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ABSTRACT
Over the past fifty years anthracyclines have been used to treat a wide variety of
cancers. Combination therapies with anthracyclines have the potential to greatly increase
treatment success. Despite the great potential of anthracyclines in the treatment of
cancer, their use has been limited due to the risk of chronic cardiotoxicity. The reduction
of anthracyclines to an alcohol metabolite has been linked to the development of
cardiotoxic side effects. One of the principal enzymes responsible for catalyzing the
formation of the anthracycline alcohol metabolite is human carbonyl reductase 1
(HCBR). Controlling the reduction of anthracyclines by HCBR may offer a means to
reduce the risk of cardiotoxicity during treatment.
The structure activity relationships responsible for the recognition and binding of
the anthracycline substrates were investigated. Molecular modeling studies implicated
Met 234 as a possible determinant of anthracycline specificity for HCBR. In order to test
this, site directed mutagenesis was used to convert the methionine to a cysteine in a
histidine expression system. The histidine tagged HCBR was found to have reduced
enzyme activity and coenzyme binding compared to native enzyme. Further, the cysteine
234 mutant enzyme was found to be inactive, although it still appeared to possess
coenzyme and anthracycline binding capability. It is clear that the addition of the
histidine tag has impaired enzyme function and that such a modification may mask any
effects introduced by mutating Met 234 to a cysteine (NIH-INBRE Grant #
P20RR16454).
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CHAPTER 1
CANCER THERAPIES: ANTHRACYCLINE TREATMENTS AND POTENTIAL
HEALTH RISKS
Anthracyclines in the Treatment of Cancer
History of Anthracycline Therapies
Anthracyclines are antibiotics that are effective treatments for a variety of
aggressive cancers.1 Among cancer treatment drugs, anthracyclines have activity on the
widest range of cancers.1 Doxorubicin has been considered the most potent neoplastic
agent in the anthracycline class of drugs and has the widest spectrum of use. 2 Only a
few types of cancers are unresponsive to anthracycline therapy. 2
Daunorubicin and doxorubicin are two types of anthracyclines that were first
isolated from the Streptomyces peucetius bacteria in the early 1960’s and are still widely
used. These two drugs are good models for cancer research because the structures of
these drugs differ by only one hydroxyl group; however, they differ in cytotoxic behavior
(Figure 1.1).1
Doxorubicin is used in the treatment of solid tumors and includes breast, lung,
thyroid, ovary carcinomas, childhood solid tumors, soft tissue sarcomas, cancers of the
blood and aggressive lymphomas. Daunorubicin is used to treat acute leukemias such as
lymphoblastic and myeloblastic leukemias.1-3 Over 2000 analogs of daunorubicin have
been made and the data show that small structural changes induce large changes in
chemical behavior. 2
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Figure 1.1: Structure of Daunorubicin and Doxorubicin

A) Daunorubicin, B) Doxorubicin
These two anthracyclines have very similar structures; however, they differ greatly in behavior (Table 1.1).
The only difference in structure between daunorubicin and doxorubicin is the addition of one hydroxyl
group on C-14.

Even though anthracyclines have been shown to be very effective in the killing of
cancer cells the clinical use of anthracyclines is limited by significant side effects for
some patients. In 1967 it was discovered that daunorubicin could induce fatal
cardiotoxicity. 2 Other analogs have been made that aim to either increase the
cytotoxicity or decrease cardiotoxicity of this treatment; however, the cardiotoxicity of
these treatments remain high. The clinical use of daunorubicin and doxorubicin covers
over fifty years and an analog that is a potent cancer cell killer and has diminished
cardiotoxicity properties has yet to be made.
Cytotoxic Mechanisms of Anthracyclines
The cytotoxicity mechanisms are not well understood for anthracyclines.
Anthracyclines are passively transported through the membrane in an uncharged form.4
pH gradients along the membrane influence the accumulation of daunorubicin in cells.4
Anthracyclines are targeted to the nucleus of the cell where it causes cell damage at the
DNA level.5 Cytotoxic mechanisms are thought to involve DNA intercalation,
interruption of the topoisomerase II enzyme and free radical production.1,6,7
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Intercalation into DNA Strands
Intercalation involves the drug inserting directly into the DNA molecule and is
essential for drug activity. Doxorubicin and daunorubicin intercalate with B-DNA and
show little affinity for A-DNA, left-handed Z-DNA and RNA duplexes.3 The
intercalation is DNA sequence specific where daunorubicin prefers to intercalate at
alternating pyrimidine-purine stretches.8 The anthraquinone intercalates between two
base pairs of DNA and prefers to bind at CPG islands.3
The amino sugar also intercalates into the DNA but the pattern of intercalation is
variable between the different drugs. The amino group determines the specific DNA
sequence to which the drug will bind.9 In both daunorubicin and doxorubicin, the amino
sugar of both drugs extends into the minor groove of DNA but the conformation of the
anthracycline molecule can vary depending on the surrounding DNA sequence.
Daunorubicin’s amino sugar has direct hydrogen bonding to the DNA while other
anthracyclines make van der Waals contact with base pairs. The hydrogen bond acceptor
varies for those drugs that have hydrogen bond contacts with the amino sugar and DNA.8
Recent studies have also focused on the role that formaldehyde may play in the
formation of DNA-adducts by anthracyclines. Studies have found that the presence of
formaldehyde aided the adduct formation when anthracyclines were present. It was
found that formaldehyde joins two anthracycline drugs together by a bridge at the 3’
amino group of the sugar group (Figure 1.2).10 The resulting molecule is called
doxoform. Doxoform then interacts with the DNA causing DNA-adducts (Figure 1.3).5
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Figure 1.2: Formaldehyde Conjugated with Doxorubicin

Formaldehyde has been found to interact with anthracycline molecules. Here formaldehyde binds the 3’
amino group of the anthracycline sugar joining two anthracycline molecules together. Doxoform(R=OH),
Daunoform (R=H). 5

Figure 1.3: Formaldehyde Aids Doxorubicin Adduct Formation

Structure of the formaldehyde-mediated doxorubicin adduct to DNA molecules. The presence of
formaldehyde may increase the ability for doxorubicin to intercalate into DNA and cause cellular damage
to cancer cells. 5

5
Cancer cells have been found to form formaldehyde. The metabolism of
anthracyclines as well as the oxidative stress induced by treatment can lead to
formaldehyde formation in the cell as well.11 The presence of formaldehyde may
increase the DNA-adduct formation and lead to increased cancer cell death.
The insertion changes the structure of DNA and inhibits the replication of cancer
cells by blocking the synthesis of macromolecules and mRNA transcription. It is
believed that intercalation interferes with DNA polymerases, DNA methyltransferases
(DNMT1), DNA ligases and helicases. DNA repair enzymes are also inhibited from
binding the anthracycline intercalated DNA and inhibits repair to damaged DNA.12 This
interruption of the DNA repair enzymes ability to function is also crucial to the
interruption of the topoisomerase II enzyme discussed below. All of these effects can lead
to cancer cell death by activating apoptotic response systems.
Interruption of the Topoisomerase II Enzyme
Anthracyclines are well known topoisomerase II poisons and this property is
believed to play a significant role in the mechanism of anthracycline cytotoxicity.1 The
role of topoisomerase II enzymes in the cell is to regulate the topology of DNA during
DNA replication and transcription activities.13 Topoisomerase II can catalyze several
reactions that include knotting and unknotting DNA, catenation and decatenation of sister
chromosomes and relaxation of super helical twists.14 The role of topoisomerase II is
essential for cell viability. Without this enzyme cells face the potential of not being able
to separate chromosomes for replication, fail to transcribe genetic information, lack the
ability to manage the topology of DNA regions and would fail to replicate.13
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One role of Topoisomerase II in the cell is to relieve stress that is produced at the
replication fork during DNA replication. During the cytotoxic response of anthracyclines
this characteristic is exploited. In the normal cell cycle, during DNA replication, DNA
helicases unwind segments of DNA for gene transcription and this process introduces
topological stress on the DNA strands. Topoisomerase II makes transient double
stranded nicks in the DNA strand ahead of the replication fork during DNA synthesis to
relieve this stress (Figure 1.4).15
Figure 1.4: Regulation of Topoisomerase II by Anthracycline Drugs

Topoisomerase II relieves stress that builds up on a DNA strand during DNA replication. This
enzyme regulates the topology of DNA by cutting a double stranded DNA segment and passing another
double strand segment through the region. The cut region is re-ligated by topoisomerase II. In this figure
the double stranded DNA segment labeled G will undergo cutting. The double stranded segment labeled T
will be passed through the G segment.
In stage 1 the two subunits of topoisomerase II come together. In step 2 the double stranded DNA
is covalently bound to the enzyme and segment G is cut. In step three the T segment of DNA is passed
through the DNA. And in step four the G segment of DNA is re-ligated. This is a reversible reaction that
requires the input of ATP.16
Anthracyclines are able to prevent the re-ligation of the strands by stabilizing form 3 of
topoisomerase II. The topoisomerase enzyme is transformed into a DNA damaging enzyme.16

The catalytic reaction of topoisomerase II occurs in discrete steps. To initiate this
reaction the enzyme forms a covalent bond between the tyrosine residues and the DNA
sugar-phosphate backbone of a double stranded region of DNA – which has been referred
to as the gate region. This is followed by topoisomerase II cutting the double stranded
DNA at the gate region, and then passing another double stranded DNA region through
the cut gate. After the duplex region has been passed through the cut DNA the covalent
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bond is reversed leading to the re-ligation of the DNA strands and the release of the
bound DNA gate region. The enzyme undergoes a conformational change so that it is
ready to start the reaction over again with another region of DNA.16
Anthracyclines are able to stabilize the enzyme-DNA covalent adduct, thus
preventing the re-ligation of the DNA strands. The anthracyclines bind the enzyme’s
active site and when the DNA strands are cut, the DNA is irreversibly, covalently bound
to the catalytic tyrosine residues in the enzyme (Figure 1.4). In the presence of
anthracyclines these topoisomerase II-DNA complexes increase in number. The result is
that topoisomerase II is transformed into a DNA damaging agent and the DNA molecules
of the cell undergo fragmentation at many different sites.17 Such DNA damage can
overwhelm the cell and will cause growth arrest in the G1 and G2 phase and ultimately
the cell will undergo apoptosis.1
Topoisomerase II poisons affect the viability of both normal cells and cancer
cells; however, the response is more pronounced in the cancer cell. There are several key
characteristics that distinguish cancer cell phenotypes from normal cells. Proliferation
states between these two types of cells can be substantially different. Cancer cells often
proliferate at an increased rate than normal cells leading to an increase in the proteins that
are needed for cell replication.18 Due to the importance of topoisomerase II in the cell
replication cycle13 this enzyme can be up-regulated in the cancer cell. Anthracycline
cytotoxicity is hypothesized to rely on the increased topoisomerase II targets to induce
the cancer cell deaths.
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Oxidative Damage and Free Electron Radical Formation
Reactive oxygen species generated by anthracycline re-dox cycling have also
been implicated in the cytotoxic mechanism of anthracyclines (Figure 1.5).1,6,7,19,20
Figure 1.5: Reactive Oxygen Generation by Doxorubicin.
e

....
HHHH
HHHH
OOOO

HHHH
OOOO

HHHH
OOOO

OOOO

OOOO CCCC

OOOO

HHHH
OOOO

HHHH
OOOO

HHHH
HHHH
OOOO

HHHH
OOOO

HHHH
OOOO

OOOO

OOOO CCCC

OOOO

OOOO

----

OOOO

OOOO

OOOO

OOOO

OOOO
HHHH
OOOO

3333

HHHH
CCCC

HHHH
OOOO

3333

HHHH
CCCC

2222

OOOO

---2222

OOOO

BBBB

2222

HHHH
NNNN

....

AAAA

2222

HHHH
NNNN

Single electron reduction/oxidation cycling between the doxorubicin quinone (A) and the semiquinone (B)
radical. This is a cyclic reaction that regenerates the parent compound and generates oxygen free radicals.
The reaction can be catalyzed by many enzymes in the body.

There is evidence that as doxorubicin is added to heart tissue in vitro superoxide
formation is increased.6 Other drugs that contained a quinone group, like daunorubicin,
were also tested and found that they significantly increased oxygen free radicals. In
addition, drugs that lack a quinone group, such as 5-iminodaunorubicin, did not
significantly increase oxygen free radicals. This data implies that in the body the quinone
group is undergoing a re-dox reaction mediated by the enzyme NADH dehydrogenase.6
The role of reactive oxygen species in anthracycline cytotoxic mechanisms is still
a matter of debate.1 Single electron re-dox cycling in anthracyclines has been
demonstrated using several different NADPH-dependent oxido-reductase enzymes found
in the body.6,7,19,20 The quinone structure acts as an electron acceptor. This forms a
semiquinone species that is highly reactive. In the presence of molecular oxygen the
semiquinone reacts to generate radical oxygen species and the parent quinone structure is
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regenerated. The parent quinone is now available to undergo another reaction in a cyclic
manner. The radical oxygen species that are generated can be superoxide anions or
hydrogen peroxide. Both of these species can be damaging to cells and are potentially
harmful to tissues.1
This re-dox cycling that occurs with the quinone has been associated with the
release of intracellular stores of iron. Anthracycline drugs bind to the free iron to form an
iron/drug complex (Figure 1.6). This complex can be very damaging to cells by
converting the superoxide anions and hydrogen peroxide species generated by the one
electron cycling events into a hydroxyl radical. A hydroxyl radical is a highly reactive
species that is more damaging than reactive oxygen species.1
Figure 1.6: Anthracyclines/Iron Complex

Doxorubicin can form complexes with iron in cells. The interaction can lead to the formation of hydroxyl
radicals and may be a potential cytotoxic mechanism. 21

Damage to lipid membranes may also occur due to these oxidative reactions. The
aglycone portion of the anthracyclines has increased lipid solubility and tends to
intercalate into the lipid membrane of the cell. The quinone portions of the drug can still
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undergo oxidation reactions creating reactive oxygen species near the membrane of the
cells. Lipid peroxidation can result and damage cancer cells.1
It is still being debated whether these free radical and oxidative reactions occur
appreciably at clinically relevant concentrations of anthracyclines. Several investigators
have made the point that the effects seen as a result of generating reactive oxygen species
are observed at anthracycline concentrations that are higher than would be achieved
during treatment in a clinical setting. Further, these free radical species have been
implicated in the mechanism of cardiotoxicity often associated with anthracycline
treatments and any cytotoxic benefit may be outweighed by the cardiotoxic effects.
Potential Side Effects of Anthracycline Therapies
Acute Side Effects of Anthracycline Treatment
Patients undergoing an anthracycline treatment regime may or may not suffer side
effects from their treatment. Some side effects are an acute response that manifest within
hours or days of beginning treatment while other side effects may occur years after
treatment.22 The most severe side effect is cardiotoxicity that can manifest itself in an
acute or chronic manner and has the potential to manifest twenty years after treatment.22
A study conducted by Griffin et.al. asked cancer patients to identify and rank the
severity of their chemotherapy side effects.23 They found that patients experienced
twenty different symptoms, thirteen were physical symptoms and seven were
psychosocial symptoms. The top five symptoms that were experienced by patients were
loss of hair, nausea, fatigue, vomiting and increased urination. The symptoms that
patients ranked as the most severe were: nausea, tiredness and loss of hair. These
researchers also found that the types of symptoms suffered or the severity of the
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symptoms did vary depending on patient factors such as age, gender, and extent of
disease.23
Nausea, Vomiting and Fatigue Symptoms Impact Patient Health
Mild or moderate nausea and vomiting are very common with anthracycline based
treatments; however, some patients suffer severe symptoms.24 These symptoms can be
controlled clinically with the prescription of anti-nausea drugs.25 Fatigue associated with
doxorubicin can affect a significant portion of patients. Studies have found that 99% of
chemotherapy patients suffer some degree of fatigue during treatment.26 Another study
reported that two thirds of breast cancer patients reported moderate or severe fatigue
during treatment.25 This symptom seems to be limited to treatment and tends to
disappear after treatment is completed;25 however, these symptoms can persist months up
to years after treatment.26 Fatigue may be due to anemia, treatment induced sleep
disturbance and depression symptoms.25
Decrease in White Blood Count and Risk of Infection
Within fourteen days patients can suffer from myelosuppression which is a drop
in white blood cell count. Most female patients undergoing treatment for breast cancer
will see their white cell count return to normal by their next anthracycline treatment. Life
threatening infections that result from the suppressed white blood cell count occurs in
less than two percent of patients.25
Ovarian Failure and Menopausal Symptoms
Doxorubicin treatment may induce ovarian failure which can mimic menopausal
symptoms and is a common side effect in women. Patients can be at an increased risk of
osteoporosis and cardiovascular disease due to this ovarian failure during treatment. Risk

factors include patient age and total dose administered.
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Clinicians can offset

menopausal symptoms by prescribing intake of calcium and vitamin D, weight bearing
exercise and monitoring bone density.25 Premature menopausal symptoms can include
amenorrhea which can be reversible or permanent. If a patient is still amenorrheic one
year after treatment they are expected to not regain ovarian function.24
Weight Gain and Risk for Secondary Disease States
Several different chemotherapy regimens can cause weight gain. Doxorubicin
can cause weight gain in breast cancer patients; however, this symptom is less
pronounced in doxorubicin treatment than with other chemotherapy treatments. Weight
gain is hypothesized to occur due to decreased physical activity, ovarian failure,
increased food consumption, reduced basal metabolic rate and a decrease in lean body
mass. Weight gain may be associated with reoccurring cancer in some patients.25
Women with breast cancer who gained greater than 5.9 kg of weight during treatment
were 1.5 times more likely to have a reoccurrence of the cancer and 1.6 times more likely
to die of breast cancer compared to woman who gained less.27 Premenopausal women
are at a higher risk for weight gain versus postmenopausal patients. Patients who
experience chemotherapy induced menopause are at the highest risk for weight gain.24
The longer drug administration times may also increase weight gain symptoms. The
increase in weight in some patients may further impact their physical health24 possibly
contributing to diabetes, cardiovascular disease and changes in orthopedics.27
Chemotherapy-Induced Leukemia
Some researchers have suggested that chemotherapy regimens such as
doxorubicin can cause chemotherapy induced acute myeloid leukemia in some patients.25
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Anthracycline therapies are believed to have a higher incidence of leukemia development
following treatment as compared to other chemotherapy treatments. 0.1% to 1.5% of
patients that have undergone standard dose anthracycline therapy are expected to develop
chemotherapy-associated leukemia;24 however, other researchers suggest that the risk is
no greater than that for the general population.25 Patients undergoing chemotherapy and
radiation; however, may be at increased risk for the development of leukemia after
treatment.25 Doxorubicin-induced leukemia is associated with changes in monocytes and
a specific cytogenic abnormality that can develop a few years after treatment.
Doxorubicin induced leukemia does not have to involve myelodysplasia which is
associated with being a precursor to the development of acute myeloid leukemia.25
Cardiotoxic Side Effects of Treatment
Anthracyclines are effective in treating a wide range of cancers; however, clinical
use is limited by a dose dependent chronic cardiotoxicity. Some groups of people have a
higher incidence of complications including younger children (less than four years), older
patients, females, and patients with a history of hypertension or cardiovascular diseases.
Cumulative dose and combination therapy have also been implicated in raising the risk of
cardiotoxicity.28 Analogs have been developed in attempts to reduce the incidence of
cardiotoxicity and include epirubicin and idarubicin; however, they have not overcome
the cardiotoxic side effect. Patients are limited to a lifetime cumulative dose that aims to
reduce their risk of developing chronic cardiotoxicity. Patients can suffer acute heart
problems or chronic heart failure that may manifest several years after completing
therapy.28
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It has been proposed that doxorubicin accumulates in the heart tissue followed by
chronic cardiomyopathy. There is evidence that this problem is correlated to dose, dose
schedule and patient age.1 Also, different patients respond differently to the anthracycline
regimens. Older people suffer different cardiomyopathies than children, females respond
differently than males, ethnicity puts some races at more risk and Down Syndrome
patients also face increased cardiomyopathies after treatment.28
Physical Manifestations of Cardiotoxicity
Hallmarks of the cardiotoxic side effects include both acute and chronic heart
failure and lead to systolic and diastolic dysfunction of the heart tissue. Cardiotoxic
damage during anthracycline treatment is believed to involve damage to the myofibrils,
sarcoplasmic reticulum and mitochondrial damage.29-33
Early cardiac dysfunction includes changes in the sarcoplasmic reticulae caused
by vacuole formation. Sarcoplasmic reticulae are part of the smooth endoplasmic
reticulum organelles found in eukaryotic cells and they are made up of tubules and
vesicles. The job of the sarcoplasmic reticulae is to store calcium ions until heart muscle
cells are stimulated when they release calcium stores driving the excitation and
contraction of heart muscle cells (Figure 1.7).34
Sarcoplasmic reticulum is composed of two parts: longitudinal tubules and
terminal cisterna (Figure 1.8). The terminal cisterna is responsible for the storage of
calcium needed to control relaxation and contraction of muscle fibers. Doxorubicin has
been found to inhibit calcium uptake and stimulate calcium release by the terminal
cisterna.

15
Figure 1.7: Doxorubicin’s Interaction with the Ca++ Channels of Sarcoplasmic
Reticulum

In the cardiotoxic response of anthracyclines, doxorubicin is believed to prevent the uptake of Ca++ into the
sarcoplasmic reticulum’s terminal cisternia. Doxorubicin is also believed to promote the release of Ca++
previously stored. This leads to an imbalance in Ca++ in the cell. 21

Figure 1.8: Structure of the Sarcoplasmic Reticulum

Muscle fibers have a structure called the sarcoplasmic reticulum that helps regulate Ca++ stores in the
muscle fibers, myofibrils. They contain two important parts: the longitudinal tubules and terminal
cisternae. Doxorubicin is hypothesized to interrupt the Ca++ channels of the terminal cisternae. Damage
from treatment can cause the sarcoplasmic reticulae to expand and displace mitochondria and other
elements from the cell. Image from: (http://www.nvo.com/jin/nss-folder/scrapbook9/m3.gif).
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The drug was not found to disrupt the function of the longitudinal tubules. It is
35

believed that hydrogen peroxides, oxidizing agents and free radicals can promote the
release of calcium in cells. All of these affects can impair contractility and cardiac
relaxation. In later stages of cardiac dysfunction, damaged sarcoplasmic reticulae can
expand in size and displace contractile elements and mitochondria in the cell.36
Mitochondria are membrane bound organelles that are considered the power
houses of cells. They are responsible for the ATP generation in cells and in very active
tissues such as heart tissues there can be several hundred mitochondria in one cell.
Mitochondria also take in calcium ions from the cytosol. During anthracycline treatment,
disruption of the mitochondria is observed where the mitochondria swell, are inhibited
from calcium uptake and formation of calcium inclusions and electron dense bodies are
observed.37 It has been found that doxorubicin interacts with the electron transport chain
found in the mitochondria (Figure 1.9). Doxorubicin can act as a final electron acceptor
in the reaction mediated by NADH dehydrogenase found at the complex I. This leads to
an oxidation reaction involving the quinone group of the anthracycline resulting in
generation of oxygen free radicals.38
Figure 1.9: Doxorubicin Interaction with Electron Transport Chain in
Mitochondria

Doxorubicin can act as a final electron acceptor in the electron transport chain at complex 1 in the
mitochondria. This reaction can generate free electron radicals that are damaging to the mitochondria and
to the cell. 39
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Mitochondria have been well established in the apoptosis response of cells. One
mechanism that these organelles use to induce apoptosis is to release cytochrome c
molecules. Cytochrome c has been well established to induce a cellular cascade that ends
with the activation of caspase-3 which induces apoptosis in cells. It has been found that
doxorubicin administration can cause the release of cytochrome c from mitochondria,
leading to activation of caspase-3, followed by cardiomyocyte apoptosis.38 This damage
to the mitochondria disrupts calcium balance in the cell, disrupts ATP production and is
believed to induce apoptosis in cardiac cells.
These early dysfunctions are followed by disorganization and degeneration of
myofibrils found in the heart muscle tissue. This damage includes less dense myofibrillar
bundles, disruption in Z-disc structures and damage to actin filaments.40 Formation of
vacuoles in the cytoplasm and an increase in the number of lysosomes are also observed.1
Combination Therapies Lead to Synergized Cardiotoxic Risk
Another promising treatment for cancer therapy involves the use of Trastuzumab
(Herceptin). This drug has been shown to be an especially promising treatment for
aggressive breast cancers; which is the second leading cause of cancer in women.41
Clinical trials have shown that this treatment has decreased the recurrence of cancer by
one half and has decreased mortality by one third in patients. Trastuzumab treatment
faces the same failings that anthracycline treatment does: cardiotoxicity.42
Trastuzumab is a monoclonal antibody that has cytotoxic effects on cells that over
express the human epidermal growth factor receptor (Her2/Neu) on cell surfaces. While
these receptors are over expressed in certain breast cancers they are also expressed in the
heart. It is this expression in the heart cell membranes which is the likely cause of the
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cardiotoxic effects seen in Trastuzumab therapy. The Trastuzumab cardiotoxicity is
interesting because the toxicity that is observed is reversible in contrast to anthracycline
toxicity which is a nonreversible event.41
One recent advance in chemotherapy treatment has been to combine Trastuzumab
treatment with anthracycline treatment; however, when these two drugs are used together
they greatly increase the risk of cardiac dysfunction in patients.41 When Trastuzumab is
used alone 7% of the patients developed heart failure, when anthracyclines are used alone
a small percentage of patients developed heart failures; however, when these two drugs
are used together 28% of the patients developed heart failure. It is hypothesized that
when these heart cells undergo another assault, such as one by anthracyclines, the effect
is synergized.43 This synergy is reflected in the dramatic increase in the percent of
patients who develop heart failures. After a combination therapy the cardiotoxicity is
also nonreversible favoring the toxicity model of anthracyclines.42 Understanding the
mechanism of cardiotoxicity in anthracycline therapies and being able to address this side
effect may considerably improve combination therapies, such as this one, leading to
increased ability to treat aggressive cancers.
Drug Resistance Side Effects Limit Effectiveness of Anthracycline Treatment
P-glycoproteins Transport Anthracyclines Out of the Cell
Patients undergoing anthracycline therapy may also face drug resistance
problems. One possible mechanism includes active drug transport of the anthracyclines
out of the cell. One such mechanism includes the multi-drug resistant (MDR) proteins
found in the membranes of cells. MDR proteins are responsible for the excretion of a
large range of drug substrates. One such MDR protein is p-glycoprotein which transports
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a wide range of substrates. Membrane transport proteins like p-glycoproteins contribute
to drug resistance by decreasing intracellular drug concentrations by an active, ATPdependent transport system.44 Several anticancer drugs have been found to be substrates
of p-glycoprotein, including doxorubicin.45 In mice undergoing treatment with
anthracyclines, it was found that doxorubicin also up-regulated p-glycoprotein
expression.46 P-glycoproteins have been shown to be expressed in the heart tissue and
the expression of these transport proteins varies between individuals. Multi-drug
resistant knockout mice, which lack p-glycoproteins, show an accumulation of
anthracyclines in the heart tissue while mice with a normal complement of p-glycoprotein
showed a reduction of intracellular levels of anthracyclines.47
The treatment of cells by an acute dose of doxorubicin has shown a sharp increase
in the expression of p-glycoproteins located in liver cells. The doxorubicin treatment
altered RNA synthesis of the p-glycoproteins as well. The results of this study indicate
that exposure to anthracyclines up-regulate the p-glycoproteins and may contribute to
drug resistance seen in patients.45
Non-MDR Protein Pumps Aid Anthracycline Resistance
There is significant evidence supporting the active transport of anthracyclines by
p-glycoproteins; however, there is also evidence that non-MDR proteins also act on the
removal of anthracyclines from the cell. One proposed protein is multidrug resistanceassociated protein which is a 190 kD membrane bound glycoprotein. It also belongs to
the ABC superfamily of proteins48 although the non-p-glycoprotein transport could
involve several different protein candidates.
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A study completed by Versantvoort investigated the drug resistance of two
multidrug resistant cell lines that did not express the p-glycoprotein.4 The investigators
made the cell membranes permeable, administered daunorubicin and then monitored the
amount of daunorubicin accumulation in the cell to indicate the efflux of the drug. Cells
that lacked the p-glycoproteins had a five fold efflux of drug compared to the controls
that express p-glycoproteins suggesting that other mechanisms of active transport are
important to daunorubicin efflux.4
Multi-drug resistant phenotypes not only efflux anthracycline molecules but also
may inhibit the cytotoxic response of anthracyclines in cancer cells. Multi-drug
resistance phenotypes have protein pumps that are located on the cell membrane. These
protein pumps respond to a broad spectrum of drugs that initiate a drug efflux response.18
Prior to anthracycline treatment, exposure to structurally and functionally unrelated drugs
can initiate the multi-drug resistance response. This can result in a faster efflux response
when the anthracycline treatment is administrated. The active transport of the
anthracyclines prevents the accumulation of the drug in the cell.4 The result is that the
number of anthracyclines molecules that make it to the nucleus are significantly reduced
preventing the cytotoxic effects on molecular targets. This decrease of anthracyclines in
the nucleus may contribute to drug resistance by demanding an increased dosage of drug
to see the same effects in patients.4
Disruption in Intracellular Distribution of Anthracyclines May Lead to Drug
Resistance
Anthracyclines are targeted to the nucleus where there are several cytotoxic
targets previously discussed. One mechanism of resistance includes the shifting of
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anthracycline location in the cell. When free drug is present in the cell anthracyclines are
found in the cytoplasm and can be sequestered in acidic vesicles or bound to membranes
of vesicles. The cells may be able to compartmentalize the drug in the cell limiting its
ability to kill cells.48
Alterations in Gene Expression of Anthracycline Targets Aid Drug Resistance
Drug resistance can also occur due to alterations in the gene expression of
anthracycline specific molecular targets. One such target is the topoisomerase II enzyme.
To decrease the cytotoxic effect of anthracyclines cancer cells can down regulate the
amount of topoisomerase expression in cells, increase the degradation of this enzyme, or
introduce mutations in the enzyme.48
Drug Metabolism May Affect Anthracycline Drug Resistance
Another mechanism of drug resistance is due to drug metabolism. Daunorubicin
treated tumor cells have an 8-fold increase in the IC50 value for the drug compared to
cells that were not pretreated with the drug. This indicated that the treated cells would
need a larger concentration of drug to achieve the same tumor cell killing results. These
treated tumor cells also showed a 6-fold increase in carbonyl reductase activity as
compared to the non-treated cells. The carbonyl reductase converts the parent drug
daunorubicin to daunorubicinol.44 This metabolite is less efficacious in cell killing
compared to the parent anthracycline. Therefore, the conversion of daunorubicin to
daunorubicinol reduces the amount of parent drug in the cell and decreases the overall
cytotoxicity.
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Proposed Mechanisms of Cardiotoxicity
The mechanism of anthracycline cardiotoxicity is not well understood. Two
prevailing hypotheses involve metabolite formation and single electron re-dox cycling
leading to the generation of reactive oxygen species.1 Several mechanisms have been
proposed that may contribute to the cardiotoxicity and a few of these mechanisms are
discussed below.
Reactive Carbonyls
Current research has focused on the metabolism of the carbonyls found in
anthracyclines because they have been linked to cardiotoxicity (Figure 1.10).
Doxorubicin and daunorubicin have two carbonyls that can be reduced by reductases in
the body: the quinone carbonyls and the C-13 carbonyl. HCBR 1 is believed to prefer the
C-13 carbonyl as a substrate compared to the quinone carbonyls.49
Figure 1.10: Reactive Carbonyls Found in the Anthracyclines
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It has been established that there are two reactive carbonyls in the anthracycline molecule. A) The quinone
structure is a carbonyl that can be reduced by different enzymes in the body. B) Carbon 13 is also a
carbonyl that can be reduced. This is an important carbonyl to this research because the reduction of this
carbonyl by HCBR 1 is linked to the cardiotoxicity observed in patients undergoing anthracycline therapy.
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Quinone Structure and the Formation of Reactive Oxygen Species Impact
Cardiotoxicity
It is also hypothesized that the quinone structure of anthracyclines undergoes
metabolism by several different enzymes in the body both cytosolic and in the
mitochondria. When the quinone undergoes a single electron reduction, reactive oxygen
species can be formed that are damaging to the tissue (Figure 1.5). Metabolism of
anthracyclines reduces the drug to a semiquinone which can react with molecular oxygen
creating superoxide species. This quinone group can undergo many re-dox cycles.50
These free radical species have been implicated in the development of cardiotoxicity
during anthracycline treatments. Plausible mechanisms include free radical peroxidation
of membrane lipids leading to the damage seen in sarcoplasmic reticulum observed
during anthracycline therapy.51
The quinone structure is believed to cause cardiotoxicity by disrupting the
calcium balance in the heart tissue. There are two prevailing ideas about the mechanism
that causes this: free radical formation or a mechanism independent of quinone derived
free radicals. It has been demonstrated that the quinone structure is necessary for
daunorubicin induced cardiotoxicity. This cardiotoxicity causes impairment of calcium
release in the sarcoplasmic reticulum but does not involve free radical damage. In studies
done by Shadle the effects of daunorubicin, a quinone containing species, and 5iminodaunorubicin, a non-quinone containing analog, were compared.52 They found that
the 5-iminoduanorubicin was less effective at causing cardiac damage than the
daunorubicin drug suggesting that the quinone structure is necessary for cardiotoxicity.
This study implies that this mechanism of cardiotoxicity involves the quinone moiety but
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is independent of free radical formation and that this mechanism disrupted the calcium
balance in the heart tissue.52
Others have shown that the single electron re-dox cycling known to occur with
the quinone in anthracyclines may contribute to anthracycline cardiotoxicity.53 In a later
study, it was established that as doxorubicin exposure in cells increased the superoxide
anion formation also increased. This study provides a link for drug exposure to the
formation of free radicals that may be toxic to cells.20
Oxygen free radicals are not the only free radicals that are formed during
anthracycline treatments. Tissues are also at risk of the formation of hydroxyl radicals
when in the presence of hydrogen peroxide and iron. It is believed that in the
mitochondria, at Complex I, the anthracycline initially undergoes reduction to form a
semiquinone species. In the mitochondria the anthracycline is an electron acceptor for
the electron transport chain (Figure 1.9).50 This semiquinone goes on to react with
molecular oxygen to form a superoxide radical as well as hydrogen peroxide.53 The
hydrogen peroxide will go on to react with iron in the cell to create hydroxyl radicals that
are damaging to tissues.20 This cascade of events may be especially damaging to heart
tissue versus other organs in the body because the heart is poorly defended against
hydroxyl radicals. The heart uses two main enzymes to detoxify oxygen free radicals:
superoxide dismutase and selenium-dependent glutathione peroxidase. Doxorubicin
treatment can decrease the concentration of the selenium dependent glutathione
peroxidase leaving the heart tissue vulnerable to the buildup of hydrogen peroxide and
lipid peroxides.54 The hydrogen peroxide can further react with iron in the cell creating
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hydroxyl radicals that lead to alterations in calcium homeostasis in mitochondria or
sarcoplasmic reticulum.20
Carbon-13 Metabolism is Linked to Cardiotoxicity
Recent research has focused on the metabolism of the C-13 carbonyl of the
anthracycline parent drugs. Anthracyclines are believed to be metabolized by several
different enzymes in the body. One important enzyme is human carbonyl reductase 1
(HCBR 1) which is believed to have activity on the quinone and C-13 carbonyls in the
drug molecule. Cells that are exposed to anthracyclines show an up-regulation of the
enzyme HCBR 1 which has been shown to reduce the parent compound to the metabolite.
The metabolite is much less efficient at killing tumor cells and has been shown to be
much more cardiotoxic than the parent anthracycline (Figure 1.11).44 A detailed
discussion of the anthracycline metabolism by HCBR 1 is provided later.
Figure 1.11: Structure of the Anthracycline Metabolite

Anthracyclines are believed to be metabolized by the enzyme HCBR 1. The result is a cardiotoxic
metabolite that is damaging to tissues and lacks cytotoxic properties. Daunorubicinol: R = CH3,
Doxorubicinol: R= CH2OH.3

Anthracycline Alcohol Metabolites are Linked to Cardiotoxic Side Effects
Other theories about cardiotoxicity rely on the formation of oxygen free radicals
as the underlying cause to heart tissue damage. However, studies that have employed
free radical scavengers have failed to prevent cardiotoxic damage at the time of
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anthracycline administration. This finding inspired a study done by Olson and coworkers
to see if another mechanism played a role in cardiotoxicity.55
This study found that doxorubicinol is more cardiotoxic to the heart tissue than
the parent drug doxorubicin. Doxorubicinol depressed systolic myocardial function in
heart muscle cells, inhibited calcium pump activity and sarcoplasmic reticulum lost the
ability to store calcium in the heart. Administration of the parent drug doxorubicin did
not show any of these acute effects.55
They also measured the ability of the heart to convert doxorubicin to
doxorubicinol and found that within 45 minutes a substantial amount of doxorubicinol
was formed. They believed that this metabolism was important to cardiac accumulation
of doxorubicinol. They also measured the ability of the metabolite to kill cancer cells and
found that doxorubicin was 5 to 28 times more cytotoxic than the metabolite.55
This study lends support to the idea that a mechanism other than free radical
formation and damage leads to cardiotoxic side effects. This study provides evidence
that the parent drug doxorubicin accumulates in the heart and that the heart has the ability
to convert the drug to doxorubicinol. Furthermore, Olson provides evidence that as the
metabolite builds in the heart a toxic threshold is meet and damage is done to ion pumps,
sarcoplasmic reticulum organelles and systolic action of the heart is inhibited.55
Human Carbonyl Reductase 1: A Carbonyl Reducing Enzyme Found in the Body
History of Human Carbonyl Reductase 1
Human carbonyl reductase 1 (HCBR; EC 1.1.1.184) is an enzyme that is a
member of the short chain dehydrogenase family (SDR) which contains a conserved
amino acid region shared by members of this family.56 The NADPH binding domain
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contains a Rossman fold with a conserved region GlyXXXGlyXGly (where X is any
amino acid) in residues at positions 12-18. Another conserved region of SDR families is
a TyrXXXLys sequence. The C-terminal portion of the enzyme has the lowest amount of
homology and may play a role in determining substrate specificity for the carbonyl
reductase enzymes.56 In the cell there are other carbonyl reducing enzymes that belong to
a separate family called the aldo-keto reductase superfamily. At one time HCBR 1 was
included in this family but was moved to the SDR family when it was found to have more
homology with members of this family.
HCBR 1 catalyzes the NADPH dependent reduction of a wide variety of carbonyl
groups. Known substrates include aromatic hydrocarbons, aldehydes, ketones, quinones
and pharmaceuticals such as anthracyclines. These substrates range from those
endogenous to the body to several xenobiotic molecules that contain carbonyl groups.
Menadione is considered an excellent substrate and is often used as a model substrate in
studies of carbonyl reductase. Catalytic amino acids include Ser 139, Tyr 193, and Lys
197. These amino acids help to transfer a hydride from the NADPH molecule to the
carbonyl carbon of the substrate and a proton to the developing alcohol metabolite.56
HCBR 1 is monomeric with a molecular weight of 30.3 kD and is found in the
cytosol of the cell. The gene encoding for HCBR 1 is located on chromosome 21
(21q22.12) and codes for a 277 amino acid protein. The enzyme is expressed in a wide
range of tissues, including brain, liver, heart, skin, and placenta. Variants of carbonyl
reductase are found throughout nature in many different taxa.57
Humans have two CBR genes, one that codes for HCBR 1 and one that codes for
HCBR 3. HCBR 3 is 62 kb downstream from HCBR 1 on chromosome 21. HCBR 3

function has not been clearly identified as of now but is currently being investigated.
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Other organisms have a gene encoding for carbonyl reductase 2; however, this gene is
lacking in humans.
Possible Functions of HCBR 1
Carbonyl reductase is believed to be involved in a variety of cellular processes
such as the metabolism of several endogenous compounds, detoxification of exogenous
carbonyl compounds, drug resistance, and signal transduction. However, a definitive role
for carbonyl reductase in humans is not well defined.56
HCBR Detoxifies Quinone Containing Compounds in the Body
It has been found that in vitro, HCBR shows activity on several quinone
containing compounds which are known to be a source of oxidative stress and therefore
are considered toxic in the body. It is hypothesized that HCBR 1 metabolism protects the
body from oxidative stress. Quinone containing compounds that are not reduced can
undergo enzyme-catalyzed single electron re-dox cycling leading to the generation of
superoxide anion and other free radicals that are damaging to tissues. The role of
detoxifying quinones by HCBR 1 has not been directly observed in human tissues;
however, HCBR 1 shows a high specificity for quinone containing compounds in in vitro
studies.58
HCBR 1 May Reduce Prostaglandins and Steroids in the Human
Carbonyl reductase has also been shown to reduce prostaglandins and steroids in
vitro as well.59 However, it is unclear if this observed activity has physiological
relevance because carbonyl reductase has low catalytic efficiencies for these substrates.60
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A Possible Neuroprotective Role for HCBR 1 – The Reduction of 4-Oxononenal
in the Brain
HCBR 1 may have different physiological roles depending in which tissue it is
located. In the brain tissue HCBR 1 is hypothesized to play a neuroprotective role. 4Oxonon-2-enal is a product of lipid peroxidation and is a brain neurotoxin. Carbonyl
reductase has been shown to reduce this compound60 to the less reactive 4-hydroxy-2nonenal and this metabolism may be protective for the brain tissue.60
The central nervous system can be vulnerable to oxidative stress because of its
high concentration of oxygen and lipids and low antioxidant defenses. A recent study
with Drosophila melanogaster has found that a CBR gene, called sniffer, may play a role
in detoxifying 4-oxonon-2-enal, a product of lipid peroxidation, which reduces neuronal
damage in normal brains. This sniffer gene has a large homology with human carbonyl
reductase and is only expressed in the brain, specifically in the entire cortex, where all
neuronal cell bodies are localized. Flies with mutations in the CBR gene had a shorter
life span and showed neurodegeneration while flies that over expressed CBR were
protected from neuronal damage caused by oxidative stress. By reducing 4-oxonon-2enal in the brain tissue, HCBR 1 may contribute to the protection of the brain from
diseases that result from oxidative stress such as Alzheimer’s, Parkinson’s or
Huntington’s disease.61
HCBR 1 has a wide variety of potential physiological substrates indicating that
the function of CBR in the body may be complicated. Further study needs to be done to
better define its physiological role.

30
Kinetic Mechanism of HCBR 1
Kinetic analysis done by Bohren et al. establishes that HCBR has a sequential
ordered Bi Bi kinetic mechanism which is a common mechanism found in NADPH
dependent dehydrogenase families (Figure 1.12).57 The coenzyme NADPH, binds to the
enzyme first and the substrate carbonyl binds to the enzyme second. The resulting
product alcohol is released before NADP+. There are three types of HCBR and this study
also found that all three forms of enzymes have the same kinetic mechanisms.57

Figure 1.12 Ordered Bi Bi Kinetic Mechanism Proposed for Human Carbonyl
Reductase.
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E represents enzyme, A is the NADPH, B is the carbonyl substrate (anthracycline), P is the product
alcohol, and Q is NADP+. Lower case “k” is the rate constant for the step. In this mechanism, NADPH
binds before the carbonyl substrate and NADP+ is release after the product alcohol.

The reaction catalyzed by HCBR 1 is a 2 electron reduction reaction, whereby the
carbonyl is converted to an alcohol (Figure 1.13). The hydride on the C4 position of the
nicotinamide ring of NADPH is transferred to the carbonyl carbon of the substrate
followed by the transfer of a proton via a proton relay system on the enzyme to the
developing alkoxide, thus yielding an alcohol metabolite.

Figure 1.13 Re-dox Reaction of HCBR 1, NADPH and Carbonyl Substrate
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HCBR 1 mediates the re-dox reaction of carbonyl compounds. A hydrogen is transferred from the NADPH
molecule to the carbonyl group. The result is an alcohol metabolite.

Human Carbonyl Reductase 1: Metabolism of Anthracyclines is Linked to
Cardiotoxicity
HCBR 1 Metabolizes Anthracyclines
Several studies have implicated HCBR 1 in the metabolism of
anthracyclines.1,49,62 This metabolism of carbon 13 leads to an alcohol product that is
damaging to heart tissue.56,63,64 Single electron re-dox cycling of the quinone carbonyls
can lead to the production of free radicals that are hypothesized to be damaging to tissues.
Recent studies have found that HCBR 1 can reduce these carbonyls as well and may
affect the generation of quinone derived reactive oxygen species.49 Given that HCBR 1
reduces both the carbonyl at C13 and the quinone carbonyls, the extent to which HCBR 1
participates in the complete metabolism of anthracyclines needs to be better understood.
In a study done by Loveless it was found that all mammalian tissues catalyzed the
reduction of daunorubicin.62 Daunorubicin is a preferred substrate than doxorubicin for
the HCBR 1 enzyme reflected by the increased kcat/Km values for daunorubicin (Table
1.1).49 All tissues showed activity on the anthracycline drugs; however, their efficiencies
did differ depending in which tissue it was found.62
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Table 1.1: HCBR 1 Kinetic Properties of Two Anthracycline Substrates
-1

kcat (s )
Km(µM)
kcat/Km(µM-1s-1)

Daunorubicin
1.27(0.03)
108(7)
1.18(0.05)x10-2

Doxorubicin
0.27(0.02)
90(16)
2.90(0.3)x10-3

Two anthracycline drugs show very different catalytic properties when metabolized by HCBR 1. These
differences are apparent even though there is a small difference in structure for these two drugs: they only
differ by one hydroxyl group on the Carbon 14 (Figure 1.1).49

Carbon 13 Metabolism of Anthracyclines by HCBR 1
Two studies have linked human carbonyl reductase levels to the development of
cardiomyopathies in mice models.64,65 In one study transgenic mice over expressed
human carbonyl reductase in the mouse heart.65 Expressing mice developed severe
cardiomyopathies and had enlarged hearts compared to normal non-expressing mice.
Immunohistochemical staining of the heart tissue of expressers showed that HCBR 1
expression was uniform, abundant and occurred in myocytes of the heart. More
importantly after a single injection of doxorubicin expressers converted 82% of
doxorubicin to doxorubicinol compared to only 5% of non-expressers. This result
correlated the increased concentration of HCBR 1 with that of the increased
doxorubicinol formation in the heart. Doxorubicinol formation was correlated to heart
damage in expressers by a serum creatine study. Elevated levels of creatine kinase are
linked to muscle damage. Expressers were found to have 60% elevated creatine levels
than nonexpressers indicating muscle damage.63
A second study involving carbonyl reductase knockout mice demonstrated that
lower CBR levels lead to protection against anthracycline cardiotoxicity.64 They found
that CBR1 (+/-) mice had lower levels of CBR and were protected from cardiotoxicity
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after exposure to doxorubicin. The knockout mice showed a decrease in circulating
metabolite after exposure to doxorubicin compared to normal (+/+) mice. It is believed
that the lower amount of CBR enzyme leads to less conversion of parent compound to
metabolite.64
A recent study provides a partial explanation for the varied response to
anthracycline cardiotoxicity observed in patients. Gonzalez-Covarrubias et. al. examined
the properties of a natural polymorphism in the human carbonyl reductase one (HCBR 1)
gene.66 They found that between different human populations there is a variation at
position 88 whereby some people have a valine and others have an isoleucine. This site
is associated with the NADPH binding in the active site of HCBR 1. This study found
that the two different forms of HCBR 1 had different Km and Vmax values for
daunorubicin. They also found that those with a valine at 88 had an increase production
of doxorubicinol when exposed to doxorubicin. The results of this study suggests that
those with the valine 88 polymorphism may be more at risk of anthracycline-associated
cardiotoxicity than those with isoleucine 88 due to the substantial increase in metabolite
formation after exposure to doxorubicin.66 Also this study shows the rational in studying
HCBR 1 by mutating key binding amino acids in the active site. Different
polymorphisms of HCBR 1 may display different specificities and kinetics for its
substrates thus revealing information about substrate binding and catalytic mechanism for
carbonyl reduction. This information can be exploited to design a more effective, less
cardiotoxic anthracycline analog.
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Specific Aims of this Project
Specific Aim 1: Molecular Modeling of HCBR 1 and Known Substrates
Using the crystallized structure of the HCBR 1 enzyme and structures of the
anthracyclines I will study the relationship between the enzyme and its substrates. The
crystallized structure of HCBR 1 has been solved and can be accessed through the RCSB
Protein Data Bank using the accession number, 1wma. This structure shows the enzyme
complex with the cofactor NADP+ and an inhibitor bound in the active site. This allows
for the structures of various substrates like menadione, daunorubicin and doxorubicin to
be aligned in the active site. Analyses can be done to determine which amino acids in the
HCBR active site appear to interact with the substrates and possibly play a role in
substrate binding and orientation.
Specific Aim 2: Design a New Expression Vector for HCBR 1
In order to facilitate purification of mutated forms of HCBR 1 a poly-histidine tag
will be added to the C-terminus of the protein to facilitate purification. Introducing
mutations into a protein has the potential to inactivate or alter the protein structure of the
enzyme and this purification system should allow for quick purification of the enzyme
regardless of its condition after purification. Specific aim 2 will address these problems
by designing a new expression vector utilizing a histidine tag added to the protein. The
protein will now be purified by a Ni2+ resin and visualization of the enzyme can be done
easily with a SDS-PAGE gel analysis.
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Specific Aim 3: Evaluate the Role of Met 234 in Doxorubicin vs. Daunorubicin
Specificity
Due to the information gained in specific aim one, specific amino acids in the
HCBR 1 enzyme were chosen to undergo mutation. I targeted position 234 which has a
native methionine. It is hypothesized that this amino acid provides steric hindrance with
substrates in the active site. It is believed that by mutating the 234 amino acid to amino
acids with smaller side chains, such as Ala, Cys, or Ser, that more room will be generated
in the active site. I expect to see increased affinity for substrates that will be measured by
an increased catalytic efficiency for substrates.
Statement of Hypothesis
Anthracyclines undergo metabolism by HCBR 1 in the body and I believe that
there are key amino acids that determine substrate specificity and help guide substrates
into the active site. I hypothesize that methionine 234 prevents the binding of different
anthracyclines due to a steric hindrance with side chains of anthracyclines. For instance,
daunorubicin has a higher specificity for HCBR 1 than doxorubicin. Modeling studies
show that the longer side chain of doxorubicin is partially hindered by its interaction with
Met 234. Such an adverse interaction is not observed with daunorubicin. If this amino
acid is mutated to smaller amino acids than more room will be generated in the active site
and an increased catalytic efficiency will be observed for the doxorubicin molecule
compared to the daunorubicin molecule.
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Summary
Carbonyl reductase plays a significant role in metabolizing anthracyclines,
lowering cytotoxic properties and increasing cardiotoxic properties of the drug and
should be a pharmacological target for improved drug design. By understanding the
relationship between HCBR and its substrates a drug can be designed that resists
metabolism and lowers anthracycline cardiotoxicity. Targeting HCBR can increase the
drugs lifespan in the cell and improve cytotoxic properties of the drug. In order to design
these new anthracycline treatments a better understanding of the kinetic mechanism of
substrate recognition and substrate binding is needed. Ultimately a drug will be designed
that is a poor substrate for HCBR and resists metabolism and/or novel inhibitors will be
identified that can block HCBR activity during anthracycline administration.
In light of the evidence that anthracycline combination therapies can be highly
effective at treating certain cancers it is clear that resolving the cardiotoxic problems can
be an important improvement to cancer therapies. This study can provide further
information about anthracyclines and their metabolism by a key enzyme. This
information can be used to enhance the cytotoxic properties and reduce risk of heart
tissue injury during therapy. New drug designs are important to providing care for
patients that would otherwise be turned down for treatment.
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CHAPTER 2
MATERIALS AND METHODS
Materials
Menadione was from Aldrich Chemical Company (Milwaukee, WI), and rutin
were obtained from Sigma Chemical Company (St. Louis, MO). Reduced β-nicotinamide
adenine dinucleotide phosphate, sodium salt, 99% (NADPH) was purchased from Life
Science Resources (Milwaukee, WI). Doxorubicin HCl and daunorubicin HCl were from
Pharmacia &Upjohn Co. (Kalamazoo,MI) and Bedford Laboratories (Bedford, OH),
respectively.
Molecular Modeling of Crystallized HCBR 1 Enzyme
Crystallized Structure of HCBR 1
The HCBR 1 enzyme has been crystallized and can be accessed at the Protein
Data Bank, www.rcsb.org/pdb, with the accession number 1WMA.67 The structure has a
bound inhibitor molecule and a bound co-enzyme molecule (NADPH) present in the
model.
Analyzing Active Site of Crystallized HCBR 1
The crystallized structure was viewed with the WinCoot program, version 0.3.3,
http://www.ysbl.york.ac.uk/~lohkamp/coot/wincoot.html. The structure of doxorubicin
was downloaded from the RCSB Protein Data Bank, accession number 1D12. Using the
bound inhibitor as a model for the position of the anthracycline C-13 carbonyl,
doxorubicin was aligned in the enzyme active site so that the carbonyl was placed near
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the known catalytic amino acids described in chapter one. The structure was analyzed for
amino acids that appear to interact with the substrate. Amino acids that were less than 3
Å from the substrate were of interest. This distance is within that expected for hydrogen
bond interactions.
Creation of an Expression System for HCBR 1
Amplification and Ligation of Human Carbonyl Reductase 1 Gene into pTrcHis2 TOPO
Vector
The HCBR 1 gene, formally isolated from the liver, was PCR amplified from the
HCBR 1 pET5a construct previously reported by Slupe et. al.49 The forward primer was
5’- GAATTCATGTCGTCCGGCATCCATGTAG-3’ and the reverse primer was 5’CCACTGTTCAACTCTCTTCTCTGA-3’.
The amplified PCR product was incubated with the pTrcHis2 TOPO vector at
room temperature for 5 minutes. The resulting ligation mixture was transformed into
Invitrogen One Shot Top10 E. coli cells and grown in SOC media in a shaker set at 37oC
and 225 rpm for thirty minutes. The growth was plated onto Luria-Bertani (LB) agar
plates supplemented with 100µg/mL of ampicillin and placed in a 37oC incubator
overnight. The resulting colonies were counted on the following day (Table 2.1).
Table 2.1: Ligation of HCBR 1 Gene and pTrcHis2 TOPO Vector
Volume of Ligation
Mixture
25µL
50 µL
100 µL
115 µl

Number of
Colonies
7
19
37
19

Ligation mixtures were inoculated into Top10 E. coli cells and were plated onto LB plates supplemented
with 100 µg/ml ampicillin and left to grow overnight in 37oC oven.
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Colonies were chosen and used to inoculate 3 mL LB-AMP broth, and allowed to
shake at 225 rpm overnight at 37oC. Plasmids were isolated from these growths with the
Eppendorf Fast Plasmid Mini standard procedure. Plasmids were screened for the correct
gene orientation using a restriction enzyme digests with EcoRI. The digests were
analyzed by gel electrophoresis using a 1% agarose gel. Correct orientation resulted in
two bands: 5 kb and 850 base pair in the lane. From this point forward the HCBR 1 gene
with histidine tag will be referred to as HCBR 1'.
Protein Expression of Native HCBR 1' and Expression of the Recombinant Protein
E. coli Growths of Native HCBR 1'
Native HCBR 1' plasmids were transformed into Invitrogen One Shot Top10
E. coli cells and plated onto LB-AMP plates. These plates were placed in 37oC incubator
overnight. One colony was used to restreak another LB-AMP plate and the resulting
colonies were used to inoculate an overnight 3 mL LB-AMP culture. After growing for
about 12 hours with shaking at 37oC, the culture was added to a 50 mL LB-AMP culture
and allowed to grow with shaking overnight at 37oC. The following morning the
overnight culture was used to inoculate 4.8 L of LB-AMP broth. Once the OD600 reached
0.6, IPTG was added to a final concentration of 1 mM. The induced cells were grown for
another 12 h before they were harvested by centrifugation at 5000 x g.
Purification of Native HCBR 1'
The cell pellet was re-suspended in a 1 mM imidazole, 50 mM NaPO4 buffer, pH
8.0 and sonicated in an ice water bath using a Misonix Sonicator 3000. The cell
suspension received 10 x 30 second pulses at a power setting of 7. A 3 minute rest period
was allowed between pulses. The resulting crude lysate was centrifuged at 50,000 x g
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for sixty minutes using a Sorvall Evolution refrigerated centrifuge. The resulting
supernatant was retained and was diluted 1:4 with a 1 mM imidazole, 50 mM NaPO4
buffer, pH 8.0. Approximated 1-2 mL of Talon Ni2+ resin was poured into a column and
equilibrated with the same buffer. The diluted lysate was added to the resin followed by
a wash with a liter of 1 mM imidazole, 50 mM NaPO4 buffer, pH 8.0.
The protein was eluted from the resin with increasing imidazole concentrations in
a 50mM NaPO4 buffer, pH 8.0. The four elution buffers used have the following
imidazole concentrations: 1 mM, 50 mM, 250 mM, and 1 M imidazole.
SDS-PAGE Analysis, Concentration, and Buffer Exchange.
The elution fractions were analyzed for protein using 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) to locate the HCBR 1' protein. The
protein of interest eluted from the column in the 50 mM imidazole, 50 mM NaPO4 buffer,
pH 8.0. The fractions containing the HCBR 1’ protein were concentrated and buffer
exchanged to 100 mM sodium phosphate, pH 7.0.
Creation and Characterization of the M234C HCBR 1´
Creation of Mutated Human Carbonyl Reductase 1 Gene Constructs
Site-Directed Mutagenesis
The QuickChange site-directed mutagenesis kit by Stratagene (Cedar Creek, TX)
was utilized to mutate the HCBR 1 gene. The amino acids that were targeted were
methionine 234, methionine 141, and tryptophan 229. This method mutates a native gene
in a vector by utilizing complimentary primers that contain a mutation. As such the
entire plasmid is copied during the process.
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Primer Design
The sequence for the native HCBR 1 gene (P16152) was downloaded from the
ExPaSy Proteomics Server (http://www.expasy.org). The codons coding for amino acids
Met 141, Met 234 and Trp 229 were located. Table 2.2 lists the primer sequences that
were designed to mutate these amino acids to alanine, cysteine, or serine.
Table 2.2: Primer Sequences for the QuickChange Mutagenesis Procedure
Intended
substitution
Met  Ala

A.A.
Position
141

Met  Ser

141

Met  Cys

141

Met  Trp

141

Met  Ala

234

Met  Cys

234

Met  Ser

234

Met  Trp

234

Trp  Ala

229

Trp  Ser

229

Forward Primer Sequence

Reverse Primer Sequence

5'GTG GTG AAC GTA TCT AGC ATC
GCG AGC GTC AGA GCC CTT AAA
AGC 3'
5' GTG GTG AAC GTA TCT AGC ATC
TCG AGC GTC AGA GCC CTT AAA
AGC 3'
5' GTG GTG AAC GTA TCT AGC ATC
TGC AGC GTC AGA GCC CTT AAA
AGC 3'
5' GTG GTG AAC GTA TCT AGC ATC
TGG AGC GTC AGA GCC CTT AAA
AGC 3'
5’
GGGTGGGTGAGAACTGACGCGGCGG
GACCCAAGGCC 3’
5’
GGGTGGGTGAGAACTGACTGCGCGG
GACCCAAGGCC 3’
5’
GGGTGGGTGAGAACTGACTCGGCGG
GACCCAAGGCC 3’
5' CCA GGG TGG GTG AGA ACT GAC
TGG GCG GGA CCC AAG GCC ACC 3'
5' CTG AAT GCC TGC TGC CCA GGG
GCG GTG AGA ACT GAC ATG GCG 3'
5' CTG AAT GCC TGC TGC CCA GGG
AGT GTG AGA ACT GAC ATG GCG 3'

5' GCT TTT AAG GGC TCT GAC GCT
CGC GAT GCT AGA TAC GTT CAC
CAC 3'
5' GCT TTT AAG GGC TCT GAC GCT
CGA GAT GCT AGA TAC GTT CAC
CAC 3'
5' GCT TTT AAG GGC TCT GAC GCT
GCA GAT
GCT AGA TAC GTT CAC CAC 3'
5' GCT TTT AAG GGC TCT GAC GCT
CCA GAT GCT AGA TAC GTT CAC
CAC 3'
5’ GGC
CTTGGGTCCCGCCGCGTCAGTTCTCA
CCCACCC 3’
5’
GGCCTTGGGTCCCGCGCAGTCAGTTC
TCACCCACCC 3’
5’
GGCCTTGGGTCCCGCGCAGTCAGTTC
TCACCCACCC 3’
5' GGT GGC CTT GGG TCC CGC CCA
GTC AGT TCT CAC CCA CCC TGG 3'
5' CGC CAT GTC AGT TCT CAC CGC
CCC TGG GCA GCA GGC ATT CAG 3'
5' CGC CAT GTC AGT TCT CAC ACT
CCC TGG GCA GCA GGC ATT CAG 3'

Primers were designed to mutate key amino acids in the native HCBR 1 gene sequence. The sites of
interest are Met 234, Met 141 and Trp 229. The letters in the bold underlined font represent the mutated
codons in the primer.

Primers were designed according to the recommendations of Stratagene for the
QuickChange II site-directed mutagenesis kit:
1) Mutation is designed into the primer and located in the middle of the primer
with approximately 15 bases flanking both sides of the mutation. The primer ends in a G
or C base. The primers anneal to the same sequence on the opposite DNA strands.

o
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2) Primers were designed with a melting temperature of greater than 78 C. The
melting temperature calculation is:
Tm = 81.5 + 0.41(%GC ) −

675
− %mismatch
N

N = primer length in bases
Thermocycling Parameters
Following the protocol provided in the QuickChange II site-directed mutagenesis
kit by Stratagene, the following were added to a 1.5mL centrifuge tube: approximately 50
ng of DNA, 100 ng of forward and reverse primer, dNTP’s, and 1.25 Units of DNA
polymerase. The reactions were placed in a thermocycler. The PCR thermocycling
settings are listed in the following table.
Segment
1
2

Cycles
1
16

Temperature
95oC
95oC
55oC
68oC

Time
30 seconds
30 seconds
1 minute
5minutes

After the PCR thermocycling was complete the reactions were placed on ice for two
minutes.
Removal of Native HCBR 1' Plasmids
In order to remove the plasmids containing the native HCBR 1 gene 0.5µL of
DPN1 restriction enzyme (10 U/µL) were added to each PCR reactions, pipetting
thoroughly to mix. The DPN1 restriction enzyme recognizes methylated plasmids. Only
the native plasmids have methylated sites and are recognized by the DPN1 restriction
enzyme and these plasmids will undergo digestion. This leaves a population of mutated
plasmids behind.
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The digestion reactions were micro-centrifuged at 7,000 x g and air bubbles were
removed. The DPN1/QuickChange II reactions were incubated at 37oC for 1 hour. After
a one hour digestion the PCR product was transformed into Stratagene XL1- Blue
Supercompetent E. coli cells and were plated on LB-AMP plates and incubated at 37oC
overnight.
Plasmid Prep Procedure
Five colonies of each mutation were selected to undergo plasmid preparation and
these plasmids were sequenced. The Promega PureYield Plasmid Midiprep System was
utilized and the standard DNA purification protocol was followed.
Gene Sequencing
The mutated plasmids were sent into Genewiz Laboratory, Genewiz inc, (South
Plainfield, NJ) for sequencing. The HCBR 1 gene was sequenced using the following
pTrcHis2 TOPO primers: Forward 5’ GAGGTATATATTAATGTATCG 3’, Reverse 5’
GATTTAATCTGTATCAGG 3’. These primers bind the vector in the flanking regions
surrounding the HCBR 1 gene. The resulting sequencing information was analyzed using
the Bioedit, version 7.0.0, software program.
An HCBR 1 gene sequence used for comparison was created from the sequence
available at Expasy.org (accession number P16152), and the bases for the histidine tag
were added to the end of the gene according to the manual provided for the pTrcHis2
TOPO vector system. This sequence was then used to align with the plasmid sequences.
When the gene was located it was analyzed for the gene mutation coding for the mutated
amino acids. The rest of the gene was analyzed to confirm that no other unattended
mutations had occurred.
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Mutant HCBR 1' Protein Expression and Purification
Protein Production
Sequenced HCBR' plasmids were transformed in Invitrogen One Shot Top10
E. coli cells and grown as described above for the modified native protein. The protein
was expressed and purified in a manner similar to that described for the native HCBR'.
Kinetic Characterization of Native and Mutant Forms of HCBR' with Menadione
Substrate
Extinction Coefficient Determination
The extinction coefficient for the HCBR 1' were estimated using the ProtParam
tools at http://ca.expasy.org. The known HCBR 1 protein sequence was downloaded
from the ExPaSy Proteomics Server, accession number P16152, and the extra amino
acids from the pTrcHis2 TOPO vector were added to the sequence. This sequence was
entered into the ProtParam tools and an extinction coefficient of 0.668 mL·mg-1 at 280
nm was estimated. The mutation was added to the sequence and was found to have an
extinction coefficient of 0.673 mL·mg-1 at 280 nm.
Specific Activity Determination and Steady State Kinetic Analysis
Reaction kinetics were measured by monitoring the change in NADPH
concentration over time spectrophotometrically (ε340 = 6220 M-1cm-1) using a Varian
Cary 100 Bio.68 Initial slopes of the progress curves were obtained from fitting the curves
to either a line or a parabola, and these slopes were used to calculate the initial velocities.
Specific activity for the modified native HCBR 1 enzyme in a standard assay comprised
of 250 µM menadione and 50 µM NADPH in 100 mM sodium phosphate, pH 8.0 was

measured and compared to that previously published.
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The extinction coefficient 0.668

mL·mg-1 was used to estimate protein concentration at 280 nm in a Cary 100
spectrophotometer. The volume of protein was varied from 3 µ l to 10 µl of enzyme and
the change in absorbance per minute was recorded. Specific activity values were
calculated for each trial.
Menadione saturation kinetics were measured using 50 µM NADPH in 100 mM
sodium phosphate and menadione concentrations ranging from 3µM to 200µM. The
resulting kinetics data were fit to the Michaelis-Menten equation (eq. 1) using the
HYPERW program.69

vo =

Vmax A
Km + A

(eq. 1)

Where νo is the initial velocity, Vmax is the maximal velocity, Km is the Michaelis
constant, and A is the substrate concentration (in this case it is menadione). From the
estimates of these constants the kcat (catalytic rate constant) and the kcat/Km (catalytic
efficiency) was calculated. The M234C mutant protein was found to be inactive under
the standard assay conditions, so several other assay conditions were investigated in an
effort to detect a measurable enzyme activity. Several concentrations of menadione and
NADPH were investigated and the assay was monitored for up to 20 minutes. Also, both
daunorubicin and doxorubicin (300 µM concentrations were used for both) were tested as
substrates. Also, dithiothreitol (up to 1 mM) was also added to the assays in case the
addition of an active-site cysteine led to unintended disulfide bond formation. The total
time for each assay measured up to 20 minutes.
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Characterization of Coenzyme and Substrate Binding
Binding of coenzyme and substrates were studied by fluorimetry. A 4 µM
solution of protein (either the native or mutant HCBR 1') was titrated with either
NADPH, NADP+, daunorubicin, or doxorubicin (concentrations ranging from 0.50 µM to
115 µM) and the resulting reduction in protein fluorescence was measured (Ex. 292 nm;
Em. 333 nm) using an Olis DM45 spectrofluorimeter (Olis, INC., Bogart, GA). The data
was fit to the Stern-Volmer equation (eq. 2) and a Kd value was determined. The
program uses a modified Stern-Volmer equation to measure the disassociation of
substrate and enzyme.

f
f1
=
fo 
B
1 +
 Kd





+ (1 − f1 )

(eq. 2)

Where f1is the fraction of protein fluorescence that is quenched, B is substrate
concentration and Kd is the dissociation binding constant for the substrate and enzyme.
Circular Dichroism of Native and M234C HCBR 1'

Circular dichroism was done to assess changes in secondary structure between the
native HCBR 1' and the M234C HCBR 1' proteins. A far UV analysis was done on the
samples which covered the 275 to 175 nm spectrum. The spectropolarimeter was
blanked with a 100 mM sodium phosphate buffer, pH 7.0 and was subtracted from the
data. 0.5 mg/mL solutions of both proteins were made and 200µL of solution was added
to a 1 mm cell that was placed in a spectropolarimeter (Jasco J810). Data was collected
at 1 wavelength per second. Two runs of three scans were collected. Each run was
averaged and then both runs were averaged.
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The raw data was analyzed by comparing the wavelength to the ∆θ
(mdeg/M*cm). The data was corrected in order to account for any miscalculations in
concentrations of the proteins. The data was also analyzed by Dichroweb,
http://www.cryst.bbk.ac.uk/cdweb/html/home.html, this website compares data to a
database of known proteins.
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CHAPTER 3
RESULTS
CREATION OF AN EXPRESSION SYSTEM FOR HCBR 1
Ligation of HCBR 1 Gene into pTrcHis2 TOPO Vector

The HCBR 1 gene was successfully amplified and inserted into the pTrcHis2
TOPO vector in the correct orientation. The histidine tag was added to the C-terminus of
the gene. Two extra amino acids were added to the N-terminus and twenty-nine amino
acids were added to the C-terminus of the enzyme. The results were verified by a
restriction enzyme digest with EcoRI and resulted in two bands at 5kB and 850 bp. The
mutations were also confirmed by sequencing of the gene in the plasmid.
Protein Expression of Native HCBR 1'

It was found that from a 4.8L culture 11 mgs of protein were obtained. The
protein was eluted from the nickel column with the lower than expected concentration of
50 mM imidazole, in 50 mM sodium phosphate, pH 8.0. At such a low concentration of
imidazole buffer it seems apparent that the native HCBR 1' protein is weakly bound to
the Ni2+ resin, perhaps because the C-terminal poly-histidine tag is partially obscured
through interactions with the remaining protein. Typically it is expected that elution will
occur in the imidazole range of 250 mM to 1 M. SDS-PAGE analysis adds more
evidence that the protein of interest was obtained at > 90% purity.
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The molecular weight of the modified enzyme is estimated to be 33.80 kD. The
major protein band that occurs is slightly above the 33 kD band in the ladder indicating
that the major band is in the correct region for the weight that is expected. The gels have
one major band occurring but there are two minor bands at 24 kD and 22 kD which
comprise < 10% of the total protein. The identity of these bands has yet to be
determined, although they may be HCBR 1' proteins that have undergone degradation
(Figure 3.1).
Figure 3.1: SDS-PAGE Gel of NHCBR'

Lane 1: Molecular Weight Ladder, EZ-run Prestained REC Protein Ladder (Fischer), Lane 2: 0.757mg/mL
NHCBR' sample, Lane 3: 0.894 mg/mL NHCBR' sample. The major band is located just slightly above
33kD band in ladder, in the region that is expected. There is a minor band at about 24kD and 22kD.

Characterization of Native HCBR 1' with Menadione Substrate

Specific Activity
The specific activity of the modified native protein was found to be 0.63 ± 0.08
µmol/mg·min. The reported specific activity in the standard assay for the HCBR 1
pET5a enzyme is 5.1 ± 0.7 µmol/mg·min.49 The specific activity for the modified native
protein is 8 fold less than that of the unmodified protein. It is hypothesized that this
lower value is due to the C-terminal peptide comprised of 29 amino acids including the
histidine tag interfering with the active site in some way.
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Steady State Kinetics Studies with the Modified Native HCBR
Table 3.1 summarizes the steady state kinetic values for both the published
unmodified HCBR enzyme49 and the His-tagged HCBR enzyme. The Km for the Histagged enzyme was found to be 3.5 fold lower than the unmodified enzyme which
indicates that this modified enzyme is reaching its maximal catalytic efficiency at lower
substrate concentrations. The kcat, turnover number, for His-tagged HCBR was seven
fold lower than that of the unmodified enzyme, indicating that the modified enzyme
produces much less product molecules in the same amount of time than that of the
unmodified enzyme. The value of kcat/Km, or catalytic efficiency, for the His-tagged
enzyme is approximately half of that observed for the unmodified enzyme. So this
suggests that overall the His-tagged enzyme is two-fold less efficient in catalyzing the
reduction of menadione as is the unmodified enzyme. This information also supports the
idea that the histidine tag may somehow interfere with enzyme catalysis.
Table 3.1: Steady State Kinetic Constants for NHCBR', M234C HCBR', and
Published HCBR 1 pET5a.

Enzyme
NHCBR'
M234C HCBR'
HCBR 1 pET5aa

Substrate
Menadione
Menadione
Menadione

kcat, s-1
0.53 ± 0.02
None
3.7 (0.1)

Km, µM
11±2
None
38 (3)

kcat/Km,
µM-1s-1
0.049 ± 0.007
None
9.8 (0.5) x 10-2

(aData from pET5a is from Slupe 2005).49 The above kinetic constants were established for the three
forms of the HCBR 1 enzyme. There is a significant difference between the pET5a enzyme and the
histidine tagged enzymes. There is a significant difference between the NHCBR 1' and the M234C HCBR'.

All of the data collected for the steady-state kinetics indicate that when the
histidine tag was added to the HCBR enzyme the efficiency of the enzyme to reduce the
substrate menadione was diminished. The substrate menadione has been used as a model
substrate to study this enzyme’s catalytic process by several different researchers. There
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are many benefits to using menadione as a substrate as opposed to using the
anthracyclines of interest. These benefits include cost, ability to dispose and safety.
Although steady state kinetics have yet to be completed using the anthracyclines it is
hypothesized that lower catalytic efficiencies will also be observed with other substrates
such as doxorubicin or daunorubicin for the His-tagged native enzyme.
Characterization of Coenzyme and Substrate Binding
Due to the diminished activity of this modified enzyme, fluorimetry was used to
look at independent binding of coenzymes and substrates to the active site. Such a
diminished catalytic efficiency and turnover number as seen for the His-tagged native
enzyme could arise if either coenzyme binding or carbonyl substrate binding were
disrupted. These series of fluorimetry studies are trying to find information about which
molecules show perturbations in enzyme binding.
Native HCBR 1 enzyme has a tryptophan (Trp 229) in the active site of the
enzyme that reports on binding to the enzyme active site. As compounds bind the active
site the fluorescence of the tryptophan is decreased. Several coenzymes/substrates were
examined. The binding of NADPH was examined (Figure 3.2) and quenching of the
enzyme was observed. Each fluorescence value is divided by the fluorescence of just
enzyme to yield the relative fluorescence, f/f0. This calculation normalizes the data.
NADPH is known to fluoresce in the same region as the HCBR enzyme. Studies
with NADP+ were done because this molecule does not fluoresce in the same region.
NADP+ is known to bind the active site like NADPH. Figure 3.3 shows the results of the
NADP+ fluorimetry study. It was expected that NADP+ quenching would mirror
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NADPH quenching. The ability to cause quenching for both of these molecules does
appear to be different.
Figure 3.2: Fluorescence Quenching of NHCBR 1' and NADPH Coenzyme

Coenzyme binding ability was expolored with fluorescence quenching studies. A 4µM NHCBR' solution
was made and a 1mM solution of NADPH was added in 1µL increments. The fluorescence values were
recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is observed.

Figure 3.3: Fluorescence Quenching of NHCBR 1' and NADP+

Coenzyme binding ability was expolored with fluorescence quenching studies. A 4µM NHCBR' solution
was made and a 1mM solution of NADP+ was added in 1µL increments. The fluorescence values were
recorded and graphed. NADP+ is prefered for fuorescence because, unlike NADPH, it does not fluoresce in
the same region has the NHCBR'. As the active site Trp 229 is quenched a decrease in fluorescence is seen.
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Next the binding of anthracycline substrates were studied by fluorimetry. There
was a significant drop in fluorescence when daunorubicin was added to the assay (Figure
3.4). When doxorubicin was added to the assay there was a drop in fluorescence but not
to the extent of the daunorubicin (Figure 3.5).
The results of the fluorimetry studies have lead to the hypothesis that the histidine
tag may potentially be interfering with the coenzyme binding site of the enzyme,
although the details of that mechanism have not been elucidated.

Figure 3.4: Fluorescence Quenching of NHCBR 1' and Daunorubicin

Substrate binding ability was expolored with fluorescence quenching studies. A 4µM NHCBR' solution
was made and a 1.24mM solution of daunorubicin was added in 1µL increments. The fluorescence values
were recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is seen.
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Figure 3.5: Fluorescence Quenching of NHCBR 1' and Doxorubicin

Substrate binding ability was expolored with fluorescence quenching studies. A 4µM NHCBR' solution
was made and a 1mM solution of doxorubicin was added in 1µL increments. The fluorescence values were
recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is observed.

Kd values were established for the coenzymes and substrates (Table 3.2). These
values reflect the disassociation of substrate from enzyme and can be represented by the
following equation:

C ↔E+S
[ E ][S ]
Kd =
[C ]

(eq. 3)

C= Enzyme/substrate complex
E= Enzyme
S= Substrate
The Kd value represents the concentration of substrate when half of the binding
sites of an enzyme are occupied. A smaller Kd value indicates a more tightly bound
substrate. The substrate has a higher affinity for the enzymes binding site than a substrate
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with a larger Kd value. The Kd value is not the preferable way to measure binding of
substrates because substrates potentially can bind active sites without being in the optimal
position for catalysis.

Table 3.2: Kd Values for the Binding of Coenzyme and Anthracyclines to Native and
M234C HCBR'
Substrate
Doxorubicin
Daunorubicin
NADP+
NADPH

Native Kd(µM)
22.67 (19.62 - 26.16)
25.45 (17.79 - 35.95)
5.49 (4.55 - 6.5)
13.58 (11.32 - 16.16 )

M234C Kd(µM)
35.8 (31.8 - 40.0)
31.5 (27.2 - 36.63)
19.53 (15.83 - 23.96)
26.83 (23.5 - 30.61)

The binding of coenzymes and substrates were assessed by fluorimetry and resulting data were fit to the
Stern-Volmer equation (eq. 3). A smaller Kd value indicates higher affinity between active site and
molecule. This data suggests that for both coenzyme and substrates the NHCBR' active site may have a
stronger affinity than the mutant. The numbers in parentheses represent the 67% confidence interval.

The scientific literature is lacking published Kd values for the unmodified enzyme
and anthracycline substrate binding. The data that was collected for the pTrcHis2 TOPO
enzyme cannot be directly compared to the pET5a HCBR; however, information can still
be gained as far as trying to identify which molecules exhibit impaired binding to the
pTrcHis2 TOPO enzyme.
Molecular Modeling of Crystallized HCBR 1 Enzyme
Molecular modeling of the HCBR 1 enzyme and the doxorubicin molecule
resulted in the identification of methionine 234 as an amino acid that potentially interacts
with bound substrates and limits the size of the substrate that can fit in the active site
(Figure 3.6).
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Figure 3.6: Models of Anthracycline Binding to the Active Site of Human Carbonyl
Reductase

Model of doxorubicin C13 carbonyl reduction by human carbonyl reductase showing the close contact
between the side chain of doxorubicin and the methionine 234 amino acid.

It was found that methionine 234 appears to interact with the C-13 side chain of
doxorubicin (Figure 3.6) in such a manner as to obstruct proper binding and orientation in
the active site required for optimal chemistry. Daunorubicin which has a smaller C-13
side chain does not appear to have such a conflict with Met 234. This may be the reason
why daunorubicin was found to be a better substrate for HCBR than was doxorubicin.49
It is hypothesized that the Met 234 limits the binding of substrates in the active site
because it sterically hinders the substrates. The Met 234 is about 3Å away from the
doxorubicin molecule which is about the distance for a hydrogen bond.
It was found that mutating methionine 234 to serine, alanine or cysteine in a
computer based model increased the space in the active site for the side chain of
doxorubicin. This increased distance is hypothesized to allow the doxorubicin more
ability to bind in the active site without interference from other amino acids in the active
site and thus allow for more optimal orientation in the active site.
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Trp 229 and Met 141 were also indentified as potentially important amino acids
(Figure 3.7). They appear to surround the aglycone structure of the anthracycline
molecules. The anthraquinone has two points that are 3Å away from both the Trp 229
and Met 141. It is hypothesized that these two amino acids help to stabilize the substrates
when they are in the active site undergoing catalysis. The mechanism of this stabilization
has not been defined to the extent of the hypothesized interaction of Met 234 and
substrate side chains discussed in this paper.

Figure 3.7: Inhibitor Binding by Human Carbonyl Reductase

Met 141
Trp 229
An inhibitor is bound to the active site of HCBR. Met 141 and Trp 229 are designated by arrows and the
inhibitor is blocked in. The pyrazolopyrimidine ring of the inhibitor is sandwiched between Met 141 and
Trp 229 side chains.

Mutating Trp 229 and Met 141 to Ala, Ser or Cys in the computer model also lead
to increased space in the active site. The hypothesis is that this larger space will allow
more space for the maneuvering of the substrate molecule leading to increased binding in
the active site.
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Characterizing the M234C HCBR 1'

Creation of Mutated Human Carbonyl Reductase 1 Gene Constructs
Site-Directed Mutagenesis of HCBR 1'
Several mutated plasmids of the HCBR 1' gene were made (Table 3.3). Several
sites were targeted. The methionine 234 site was successfully mutated to cysteine,
alanine, serine and tryptophan. The methionine 141 site was successfully made into
serine, tryptophan, alanine, and cysteine. The tryptophan 229 site has not been mutated
as of now. One double mutant was created – S141/S229. The large numbers of mutated
colonies on the mutated plates was a good indication that the procedure was successful.
The DPN1 control had the same concentration of native plasmid and underwent the PCR
procedure without any primers followed by DPN1 digestion. There were five or less
colonies on theses plates indicating that the DPN1 restriction enzyme was able to digest
all parental DNA in the PCR reactions. Five colonies were chosen from each mutation
and the plasmids were purified and the genes were sequenced.
Table 3.4 summarizes the sequencing results of these plasmids. Most plasmids
contained the desired mutation although a small number of plasmids did not. Some
plasmids that were sent in did not result in a clear enough sequence for analysis which
may be due to improper preparation of plasmid prior to sequencing. At least one colony
of each desired mutation was created and had the correct sequence for the rest of the
gene. The double mutated plasmid did not have a clear enough sequence to insure that
both mutations are present. They will need to undergo further sequencing to confirm the
results.

59
Table 3.3: Results of the Quick Change Mutagenesis Procedure

PCR Reaction
S141,E244 HCBR'
A234,E244 HCBR'
S 234,E244 HCBR'
C234,E244 HCBR'
DPN1 Control
E. coli only Control

PCR Reaction
Trp141,E244 HCBR'
A141,E244 HBCR'
S141, E244 HCBR'
Trp234, HCBR'
C141, E244, HCBR'

Number of
Plates

2
2
2
2
2
2
Number of
Plates

Number of Colonies
155
195
398
274
less than 5 colonies
None

Expectations
Hundreds
Hundreds
Hundreds
Hundreds
None
None

Number of Colonies

2
2
2
2
2

Expectations
18 Hundreds
13 Hundreds
136 Hundreds
6 Hundreds
43 Hundreds

DPN1 Control

2

None None

E. coli only control

2

None None

Under optimal conditions the quick change mutagenesis protocol produces several hundred colonies of
mutated plasmids. The large number of plasmids that resulted in the mutated plates was good evidence that
the mutations worked. A DPN1 control utilized native template plasmid and underwent the DPN1
digestion. The low recovery of colonies indicates that the DPN1 was able to efficiently digest all native
plasmids.

Protein Expression
M234C HCBR 1' Protein Production
To better identify mutated enzyme production the HCBR 1 gene was inserted into
the pTrcHis2 TOPO vector. The advantage of adding a histidine tag to the gene allowed
the enzyme to bind a Ni2+ column. It helps in several regards, first it immediately
separates bacterial carbonyl reductases from HCBR 1 and second it is easy to sample the
fractions on an SDS-PAGE gel allowing the visualization of the mutated proteins
regardless of activity.
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It was found that a 4.8L of culture yielded about 9.5 mg of mutated protein. As
with the native His-tagged construct, the protein eluted from the nickel column with the
50 mM imidazole, 50 mM sodium phosphate, pH 8.0 buffer. It also shows weak binding
to the column by the fact that it eluted off the column in a low imidazole buffer.
SDS-PAGE analysis provided more evidence that the protein band observed in
the SDS-PAGE gel is the targeted protein, M234C HCBR'. Figure 3.8 shows the results
of the SDS-PAGE. Lane 1 is the Fischer EZ Run pre-stained REC protein ladder. Lane
2 is the M234C HCBR 1' sample, Lane 3 is the NHCBR' sample. The banding pattern of
the native and the mutant are similar. They both have a major band slightly above the 33
kD ladder band. They both show the same minor bands occurring about 24 kD and 22
kD. The estimated molecular weight of the mutant is 33.64 kD. The gel reflects that the
major band for the mutant is in this region.

Figure 3.8: SDS-PAGE Gel of M234C and NHCBR'

Above is an SDS-PAGE gel of the M234C and the native HCBR 1'. Lane 1: Fischer EZ Run Prestained
REC protein ladder. Lane 2:M234C HCBR 1' and Lane 3: NHCBR'. The bands appear in the 33kD region
as expected.
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Table 3.4: Sequencing Results of the Mutated HCBR 1' Plasmids

Plasmid name

Colony Number

Sequence Correct for Mutation

A234,E244 HCBR'

1

Yes

A234,E244 HCBR'

2

Yes

A234,E244 HCBR'

3

Yes

C234, E244 HCBR'

1

Yes

C234, E244 HCBR'

2

Yes

C234, E244 HCBR'

4

Yes

S141, E244 HCBR'

2

Yes

S234, E244 HCBR'

1

Yes

S234, E244 HCBR'

2

Yes

S234, E244 HCBR'

3

Yes

S234, E244 HCBR'

4

Yes

Trp234, E244 HCBR'

1

Yes

Trp234, E244 HCBR'

2

Yes

Trp234, E244 HCBR'

3

Yes

Trp234, E244 HCBR'

4

Yes

A141,E244 HCBR'

1

Yes

A141,E244 HCBR'

3

Yes

A141,E244 HCBR'

4

Yes

C141,E244 HCBR'

1

Yes

C141,E244 HCBR'

2

Yes

C141,E244 HCBR'

3

Yes

C141,E244 HCBR'

4

Yes

Trp141, E244 HCBR'

1

Yes

Trp141, E244 HCBR'

2

Yes

Trp141, E244 HCBR'

3

Yes

Trp141, E244 HCBR'

4

Yes

Plasmids were sequenced to identify that the correct mutation was present in the plasmid. The gene was
also analyzed to confirm that no other unintended mutations had occurred.
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Characterization of M234C HCBR 1' Protein

Activity Studies
Menadione Activity Study
The M234C HCBR 1' enzyme was first assayed with the standard enzyme assay
that has been previously established.49 The 234 mutant did not display any measurable
activity with the standard assay protocols with assay times up to 10 minutes.
The assay was then modified by varying the concentration of menadione from 25
µM to 180 µM. This lower range of menadione concentrations was selected to control
for possible substrate inhibition. Even after 20 minutes, no measurable enzyme activity
was detected.
NADPH Activity Study
A wide range of NADPH concentrations were also explored in order to test
possible problems with the binding of coenzyme NADPH. The NADPH concentration
was increased from the standard assay to see if there is any activity with the M234C
HCBR 1'. The NADPH concentration ranged from 300 µM to 500 µM. Again, no
measurable activity was recorded from the mutant.
Anthracycline Activity Studies
An assay was done with both doxorubicin and daunorubicin. The assays were
done under standard assay conditions and 300 µM anthracycline in place of menadione.
Also NADPH concentrations were increased from 50 µM to 150 µM. As with all other
attempts, no activity was recorded with this mutant.
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DTT Activity Study
An assay was done with the compound dithiothreitol (DTT) was used to assay any
disulfide bonds that may have been formed due to the addition of the Cys 234 mutation.
It is not believed that HCBR has any naturally occurring disulfide bonds and so DTT is
not hypothesized to interfere with the activity of the protein. There was no activity
observable with pre-incubation of the enzyme with DTT.
Fluorimetry Studies

NADPH Fluorimetry
As with the native His-tagged construct, the coenzyme and substrate binding
properties of the Cys 234 mutant enzyme were investigated using fluorimetry. Figure 3.9
shows the fluorescence quenching as the NADPH is added. From this data a Kd was
estimated to be 26.83 µM (Table 3.2).
A previously reported Kd for a variant of HCBR1, also with a histidine tag, was
6.3 ± 0.6µM for CBR1 V88 and 3.8 ± 0.5µM for CBR1 I88 (Covarrubias et. al. 2007).
These researchers added a 6x His-tag to the N-terminus of the HCBR1 protein by
inserting the gene into a pET28 vector. This vector adds the His-tag to the N-terminus of
the enzyme and also adds between 10-24 extra amino acids.
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Figure 3.9: Fluorescence of M234C HCBR 1' and NADPH Coenzyme

Coenzyme binding ability was expolored with fluorescence quenching studies. A 4µM M234C HCBR'
solution was made and a 1mM solution of NADPH was added in 1µL increments. The fluorescence
values were recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is
observed.

The Kd values reported in the Gonzalez-Covarrubias are smaller Kd values than
the Kd values that were observed in this study (Table 3.2). This smaller Kd value may
indicate that the pTricHis2 TOPO His-tag used in this research may have a lower affinity
for the binding of the coenzyme reflected by the increased Kd values. Within this
research the coenzyme Kd values vary for the native and the M234C indicating that there
is a difference in affinity between these two species (Table 3.2). The Kd values indicate
that the NADPH coenzyme is binding the M234C HCBR 1' with less affinity than the
native HCBR1' enzyme. This may indicate a disruption in the coenzyme binding site and
it is hypothesized that this interruption is due to the polyhistidine tag, although the
mechanism for this disruption has not been worked out yet. This data about the binding
of NADPH to the mutated enzyme further supports the diminished kinetic activity
observed in the NHCBR 1' enzyme. There is evidence to support the hypothesis that the
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polyhistidine tag added to both of these enzymes is interfering with the binding of the
cofactor.
NADP+ Fluorimetry
Fluorimetry studies with the molecule NADP+ and HCBR 1 have been completed
in this lab before; however, the information has not been published. NADP+ is a product
for the enzyme re-dox reaction and shares close structure with NADPH, varying only by
a hydrogen and charge. It is preferred to complete fluorescence quenching studies with
NADP+ because it does not fluoresce in the same region as HCBR 1. It is expected that
HCBR 1 enzyme will bind the NADP+ with similar affinity as the NADPH molecule. It
is expected that binding of the NADP+ will lead to quenching of the enzyme fluorescence
(Figure 3.10).
The NADP+ fluorescence quenching data suggests that the HCBR 1' is binding the
NADP+ molecule with a higher affinity than it binds the NADPH molecule (Table 3.2).
Figure 3.10: Fluorescence of M234C HCBR 1' and NADP+

Coenzyme binding ability was expolored with fluorescence quenching studies. A 4µM M234C HCBR'
solution was made and a 1mM solution of NADP+ was added in 1µL increments. The fluorescence values
were recorded and graphed. NADP+ is preferred in fluorescence studies because it does not fluoresce in the
same region as the protein. As the active site Trp 229 is quenched a decrease in fluorescence is seen.
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Anthracycline Binding by Mutant HCBR
An intrinsic protein fluorescence quenching assay was done with the
anthracyclines daunorubicin and doxorubicin. Both effectively quench the protein
fluorescence (Figures 3.11 and 3.12). Kd values were found to be 35.8 µM and 31.5 µM
for doxorubicin and daunorubicin, respectively (Table 3.2).

Figure 3.11: Fluorescence of M234C HCBR 1' and Daunorubicin

Substrate binding ability was expolored with fluorescence quenching studies. A 4µM M234C HCBR'
solution was made and a 1.24mM solution of daunorubicin was added in 1µL increments. The
fluorescence values were recorded and graphed. As the active site Trp 229 is quenched a decrease in
fluorescence is observed.
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Figure 3.12: Fluorescence of M234C HCBR 1' and Doxorubicin

Substrate binding ability was expolored with fluorescence quenching studies. A 4µM M234C HCBR'
solution was made and a 1mM solution of doxorubicin was added in 1µL increments. The fluorescence
values were recorded and graphed. As the active site Trp 229 is quenched a decrease in fluorescence is
observed.

There is no previously published data from which a comparison can be made
regarding these Kd values. The decrease in fluorescence as the substrate was added is
good evidence that the substrates are able to bind the mutant. The Kd values can be
deceiving; however, because this study doesn’t insure that optimal binding for catalysis
has occurred in the active site. A substrate can bind without optimal position for catalytic
reactions to occur but still induce fluorescence. Based on comparison to the
anthracycline Kd values obtained for the native HCBR', there may be a modest decrease
in anthracycline binding affinity when methionine 234 is mutated to cysteine. The results
from these experiments do not support the hypothesis to specific aim 3. It was
hypothesized that the M234C HCBR 1' would allow more room in the active site for the
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substrate doxorubicin to bind. However, Kd values in this study do not show a significant
difference between the two anthracycline substrates.
Circular Dichroism of Native HCBR' and M234C HCBR 1'

The circular dichroism technique was used to assess any difference in secondary
structure between the NHCBR' and the M234C HCBR' enzyme. These enzymes are the
same with the exception that the mutant has a cysteine amino acid at position 234. This
experiment was trying to confirm that the mutated enzyme was folded correctly. It was
found that there was no significant difference in secondary structure between the two
enzymes (Figure 3.13).

Figure 3.13: Circular Dichrosim of Native and M234C HCBR 1'
Overlay of NHCBR and M234C HCBR
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It was found that there was no significant difference in secondary structure between native and M234C
HCBR 1'.
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This may be evidence that the mutated enzyme is folded correctly in reference to the
NHCBR' enzyme. This is evidence that the lack of activity that is seen in the mutant
compared to the native may be indicative that amino acid 234 has an important role in
docking substrates in the active site. It has been observed that when the methionine 234
is mutated to a cysteine that there is no observable activity in the mutant.
Conclusion for Results

The results of these studies indicate that the NCHBR 1' enzyme does not behave
the same as the previously published HCBR1 enzyme.49 This histidine modified enzyme;
however, still shows activity with the known substrate menadione and NADPH, even
though the binding of the NADPH molecule may be somewhat perturbed. The M234C
HCBR' enzyme also has been affected by the addition of the histidine tag; however, when
compared to the native enzyme with histidine tag the mutant does not show any
observable activity. This difference in kinetic behavior between these two histidine
tagged enzymes is important and may be preliminary evidence that suggests that position
234 in the HCBR 1 enzyme is an important amino acid that helps control substrate
binding in the enzyme active site.
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CHAPTER 4
DISCUSSION
DESIGNING A POOR ANTRHACYCLINE SUBSTRATE FOR HUMAN
CARBONYL REDUCTASE 1
Application of the Structure-Based Drug Design for HCBR 1

Structure based drug designs give researchers an information guided approach to
the study of their biological target, quite often times a protein. Bioinformatics servers
store large amount of data about a protein that many separate researchers are studying.
Structural information can be used to categorize the protein into a protein family. Protein
families and superfamilies are composed of proteins that have a high degree of similarity
due to conserved regions and domains found within the protein. Once a protein has been
put into a family insights can many times be gained about the structure/function
relationships of the protein based on the highly conserved regions and the corresponding
functions in other members of that family.70
SDR Superfamily Characteristics
HCBR 1 (E.C. 1.1.1.184) is a member of the SDR superfamily of proteins which
consists of over 3000 members. The SDR family is ubiquitous, occurring in both
prokaryotic and eukaryotic organisms. They have a role in the metabolism of a wide
range of biological compounds including alcohols, sugars, aromatic hydrocarbons,
steroids, and prostaglandins. All SDR proteins share conserved primary structural
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elements that indicate common fold, active site, reaction mechanism, and cosubstrate/substrate binding regions. The general structure is a cofactor-binding region in
the N-terminus, catalytic active site in the central portion and a substrate binding region
of the C-terminus. Those members that are oligimers have a C-terminal extension that
allows for binding subunits. The C-terminal region of the SDRs has the greatest
variability.71
The catalytic residues of SDRs are found in a region comprised of a conserved
Tyr-x-x-x-Lys region. The Tyr residue exists in an ionized form which is stabilized by
the side chain of the Lys (Figure 4.1). The positive charge of the Lys attracts the oxygen
of the carbonyl substrate establishing a partial positive charge on the carbon and a partial
negative charge on the oxygen. This allows for a nucleophillic attack from the hydride of
the NADPH nicotinamide ring.72
Figure 4.1 Nucleophillic Attack of the Substrate

The active site of SDR proteins have a conserved Tyr-x-x-x-Lys residues. The sidechain of the Lys residue
stabilizes the ionized form of the Tyr residue. The oxygen of the carbonyl group is attracted to the Tyr
residue creating a slightly negative charge on the oxygen. This leaves a partial positive charge on the
carbon. The H atom of the NADPH initiates a nucleophillic attack on the carbonyl group and a proton is
donated from the Tyr residue. 72
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Analyzing the HCBR 1 Crystallized Structure
The RCSB Protein Databank has a x-ray crystal structure of HCBR 1 submitted
by Tanaka et.al.67 This structure is important to the research discussed in this thesis
because it has both a bound inhibitor molecule and the bound coenzyme, NADPH. This
information confirms the active site for both the cofactor NADPH and the active site for
the substrate. Examination of this active site structure of HCBR 1 has lead to the
identification of what are believed to be the catalytic amino acids.
The HCBR 1 enzyme catalyzes the transfer of the pro-4S-hydrogen atom of the
nicotinamide ring of NADPH to the carbonyl carbon of the substrate.59 In the literature a
catalytic triad of amino acids have been described, namely Tyr 193, Ser 139, and Lys
197.56,67,73 This region is a homologous region that has been found throughout the
carbonyl reductase families. The role of these enzymes is to facilitate the movement of a
proton from the hypothesized proton donor, Tyr 193, to the oxygen of the substrate
carbonyl through a hydrogen bonding network (Figure 4.2).

Figure 4.2: Daunorubicin Reduction by HCBR 1

HCBR 1 catalyzes the reduction of anthracyclines at the C-13 carbonyl. A hydride is transferred from the
Pro-4S-H atom of the NADPH nicotinamide ring. The hydride acts as a nucleophile that attacks the
slightly positive C-13 carbonyl. This pushes electrons from the double bond to the oxygen. The oxygen
accepts a proton from the Tyr 193 amino acid in the HCBR 1 active site.
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Analysis of the Active Site of HCBR 1
The x-ray crystal structure of HCBR was used in the computer program Wincoot
to dock the known substrate doxorubicin and daunorubicin. Using the bound inhibitor as
a model the C-13 carbonyl that is known to undergo reduction by HCBR 1 was aligned in
the correct position. The research conducted by Slupe et.al.49 has established that the C13 carbonyl of anthracyclines is the preferred substrate over that of the quinone carbonyls
for HCBR 1. Examinations of the interaction of the anthracyclines and amino acids in
the active site led to the identification of Met 234, Met 141 and Trp 229 as potential
amino acids that play a significant role in recognizing and docking substrates in the active
site. This analysis has also led to the hypothesis that site 234 selects substrates due to
steric interference. It was noted that the anthracycline daunorubicin is a better substrate
for this enzyme than doxorubicin represented by its higher catalytic efficiency value.49
The only difference in these molecules is that daunorubicin lacks the alcohol group
attached to C-13 side chain observed in the doxorubicin molecule. This difference in
structure has led to the postulation that the alcohol group on the C-13 side chain of
doxorubicin interferes with Met 234 and disrupts optimal binding for catalysis. It is
hypothesized that this interaction leads to the lowered catalytic efficiency as compared to
that for daunorubicin. This research project used site-directed mutagenesis procedures to
mutate the amino acids to those with a smaller side chain to test the steric hindrance
hypothesis. The research examining the changes in enzyme behavior due to the sitedirected mutagenesis is still ongoing.
Recently Carlquist and coworkers undertook a computational chemistry
experiment where they used the computer program ArgusLab 4.0.1 to dock known

flavonoid inhibitors into the active site of HCBR 1.
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Their results also suggest that Met

234 and Trp 229 may play a significant role in binding substrates/inhibitors in the active
site. Unlike our hypothesis, they suggest that these amino acids participate in chemical
interactions with the substrates by anchoring the substrate with hydrogen bonds. They
postulate that the Trp 229 residue participates in aromatic-aromatic interactions to
increase affinity with the substrates.74 Their recognition of these two amino acids as
being important to substrate-enzyme interactions agrees with our hypothesis that these
amino acids play a significant role in substrate binding. We do disagree with the
mechanism that these amino acids use to interact with the substrate – especially the Met
234 site.
Receptor-Based Drug Design Cycle

The receptor-based drug design cycle focuses on small, nonprotein ligands. A 3D structure of a protein-ligand complex is used as the basis for the rational design of a
new ligand. The information that is gathered is then used to synthesize a new drug
candidate with features that are believed to be beneficial. To test a hypothesis about the
new drug design site-directed mutagenesis of the enzyme is often used and data about the
enzyme-ligand interaction is collected.75
The research of HCBR 1 is also utilizing a receptor-based drug design. The
literature states that HCBR 1 is known to be a promiscuous enzyme having a large range
of unrelated substrates in the laboratory. Although a lot of substrates have been
identified in the laboratory setting the physiological role and the actual physiological
substrates have yet to be identified.
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In this project we are aiming to learn about the chemical interactions that occur
between the anthracyclines and HCBR 1. Concerning the Met 234 site we believe that
this amino acid sterically hinders the binding of doxorubicin due to the extra alcohol
group on the C-13 side chain leading to a lower catalytic efficiency compared to
daunorubicin. The end result is the hope that a new anthracycline drug analog can be
designed that changes the C-13 side chain perhaps by adding a bulky residue.
Designing analogs of anthracyclines is not new. Over 2000 anthracyclines have
undergone similar modifications.1 The goal of all of these analogs was to reduce the
cardiotoxic side effects that are observed in anthracycline treatment.2 Researchers have
added large chemical groups to different parts of the drug such as the amino group, the
sugar moiety or the aglycone group.2 The hope was that the anthracycline derivatives
would have a lower cardiotoxic side effect but have the same or improved cytotoxic
properties.1 Data has shown that these derivatives have not always changed the
cardiotoxic properties, on an equivalent drug dosage, and in many cases have
significantly decreased the cytoxic properties of the anthracycline.
We hope that our approach will result in a different outcome for our designed
anthracycline derivative. The C-13 side chain is one region that has not been altered in
the other derivatives. We believe that our rational drug design has given substantial
support for the changing of the C-13 side chain. If the future kinetic data supports our
hypothesis, we would consider adding a bulky group to the C-13 side chain to prevent the
binding of the anthracycline in the active site of HCBR 1. This in turn would prevent the
metabolism of anthracyclines by HCBR 1. We believe that this analog would directly
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address the issue of cardiotoxicity because data suggest that C-13 metabolism is a major
driving force in the cardiotoxic side effects seen in anthracycline treatment.
Design of Ineffective Substrate
The goal of this research project is to collect information about the mechanism of
HCBR 1 anthracycline specificity so that a new anthracycline analog can be designed.
The goal is that the new analog is an ineffective substrate for HCBR 1. The result will be
a new anthracycline analog that no longer fits into the active site and resists metabolism
to an alcohol product. The challenge is designing an anthracycline that maintains its
cytotoxic behavior and reduces or eliminates its cardiotoxic side effects.
Research shows that there is significant evidence that the HCBR 1 enzyme has a
significant role in metabolizing anthracyclines to an alcohol product in the cell. There is
significant evidence that this alcohol product is a significant cause of the cardiotoxicity
observed in the heart tissue of some patients. This research suggests that the C-13 side
chain has an important role in the binding of the anthracycline to the HCBR 1 enzyme
and modifications to the anthracyclines C-13 should be explored with the end goal of
creating an ineffective substrate for HCBR 1.
Analyses of the Activity of M234C HCBR 1'

Mutating Site 234 to Cysteine Yields No Discernable Activity to Date
To explore the relationship of the Met 234 and its interactions with substrates the
HCBR 1 enzyme was successfully mutated to Cys 234, Ala 234, Ser 234 and Trp 234.
To date only the activity of M234C has been addressed. Research is ongoing to explore
the activity changes of the Ala 234, Ser 234 and Trp 234.
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The pTrcHis2 TOPO system was used to add the histidine tag to the end of the
HCBR 1 gene. The histidine tag was successfully added to the C-terminus of the protein.
This kit also adds two extra amino acids to the N-terminus and 23 extra amino acids
before the six histidines on the C-terminus end of the protein. The extra 23 amino acids
are epitopes that are used to bind antibodies for western blot procedures. There is more
than one way to attach a histidine tag to the end of a protein including vectors like the
pTrcHis TOPO as well as conventional PCR reactions. Addition of a histidine tag by
PCR utilizes primers designed with a histidine overhang. As the gene is amplified the
histidine tag is incorporated into the gene. The pTrcHis TOPO kit was chosen because it
has been used in a neighboring lab without significant impacts on the expression of the
protein.
Possible Complications Inhibiting M234C Activity
During the course of this research it was found that the histidine tag added by the
vector may be interfering with the activity of the NHCBR. It has been found that
choosing to use the pTrcHis2 TOPO vector system has proved to have some inherent
problems for this enzyme. Our data shows evidence that the histidine tag got in the way
of catalysis by interrupting the binding of the NADPH cofactor. This discovery
complicates the analysis of results seen for the 234 mutations.
Several of the results suggest that the M234C mutation does not have activity that
can be measured by the techniques used in this laboratory. The His-tagged native HCBR
protein, even though activity was decreased due to the histidine tag, did show a
measurable amount of activity. It remains possible that if other more sensitive techniques
such as fluorimetry for measuring enzyme activity were used, perhaps activity for
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M234C could be measured. It is worth noting that M234C is the only 234 mutant that
was fully characterized. There is preliminary data to suggest that the Ala 234 mutation
also appears to lack activity; however, more studies need to be done to support this claim.
If the result that the M234C HCBR' has no activity holds true then the following
may be concluded. One possibility is that the Met 234 makes an important interaction in
positioning compounds in the active site as previously suggested.74 If so, our hypothesis
that Met 234 acts to restrict the size of substrate that can productively bind in the active
site through sterics is not correct. Another possibility is that Met 234 assists in coenzyme
binding in some way and its role is essential to the catalytic activity of the enzyme. This
option is supported in part by our fluorescence quenching studies. And yet another
plausible explanation is that Met 234 is required for the structural integrity of the active
site and that changing it to cysteine disrupted this structure, thereby rendering the enzyme
inactive. More work needs to be done in order to resolve this problem.
M234C May Display Substrate Binding Ability
After the realization that the histidine tag interfered with the native HCBR 1'
expression fluorimetry studies were done to try and assess the ability of the NADPH and
NADP+ cofactor binding and substrate binding independent of each other. Kd values, a
rate constant that represents the dissociation of substrates from enzymes, were generated
from the data collected. A smaller Kd value indicates a greater affinity for that substrate.
Due to the fact that the environment of the coenzyme binding pocket and the
substrate binding pocket are different Kd values cannot be directly compared between
these two different active sites in the enzyme. However, the experiments are trying to
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assess the ability of both the native and M234C HCBR' enzyme to bind these substrates
independently.
In the native HCBR' NADP+ has twice the affinity than the NADPH molecule.
We were expecting that NADP+ and NADPH would bind the enzyme with similar
affinity. We choose to use both the NADPH and NADP+ because NADPH fluoresces in
the same region as the HCBR 1 enzyme, whereas NADP+ does not fluoresce in the same
region. NADP+ only differs from NADPH by one hydrogen and it possesses a positive
charge on the nicotinamide ring. It is known that the NADP+ is able to bind the HCBR 1
enzyme lacking the histidine tag. The fact that we see a difference in affinity between
these two coenzymes in the HCBR' is surprising and may indicate that this form of
enzyme is not binding the coenzyme as efficiently as HCBR. The results do show that
the HCBR' is not completely unable to bind the coenzyme. This information coupled to
the fact that the HCBR' has decreased activity may indicate that the coenzyme binding
site has been interrupted by the addition of the histidine tag.
The M234C HCBR' was expected to have the same Kd values for the coenzymes.
The mutations that are introduced at the 234 site are not hypothesized to affect the
binding site of the coenzyme. M234C did not have as large of a difference between the
affinities of NADPH and NADP+; however, there was a difference between the Kd
values. These may indicate that the M234C has different affinities for the two different
coenzymes.
The native enzyme displayed more affinity for both the coenzymes as compared
to the M234C. Considering the NADPH data the native HCBR' has twice the affinity
than the mutant. For NADP+ the native has four times the affinity than the mutant.
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The hypothesis for this series of fluorimetry studies was that the native and
M234C HCBR' enzymes would bind the coenzyme in the same or very similar manner.
These data results raise the question as to why the native has more affinity for both
coenzymes than the mutant. Both of these enzymes are in the same histidine tag system
and are hypothesized to be affected by the histidine tag in the same manner; however,
they clearly show a difference in the ability to bind coenzymes. This data may suggest
that the M234C has some perturbation in the coenzyme active site leading to a decrease
in binding ability of the coenzymes. More studies will need to be done to substantiate
any changes in the mutant coenzyme site.
The coenzyme site is located near the N-terminus region of the protein and the
histidine tag was added to the C-terminus of the protein. It was not assumed that the
histidine tag would affect the coenzyme site in any way; however, I believe that there is
evidence that the histidine tag is interfering with the active site in some way. Any
changes that may have occurred in the coenzyme binding site have not been defined as of
yet. The mechanism of the interference that the histidine tag may or may not have with
the coenzyme site has not been defined as of now.
The ability of the native and mutant HCBR' enzymes ability to bind anthracycline
substrates were also investigated. In the native HCBR' daunorubicin and doxorubicin
have about the same affinities for the active site. Although it is important to consider that
the doxorubicin error on this data is larger than the NADP+ data. Steady state kinetics
concerning the HCBR enzyme and anthracyclines indicate that daunorubicin is a better
catalytic substrate than doxorubicin reflected by a larger catalytic efficiency value. Due
to this information, I was expecting that daunorubicin would have a higher affinity for the
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substrate active site than doxorubicin; however, the fluorimetry data does not support this
idea.
The M234C enzyme has a similar trend concerning the affinities of the two
anthracycline substrates. Daunorubicin and doxorubicin have essentially the same Kd
value; although, daunorubicin has a slightly increased affinity. In this data the error
values are very comparable as well. Unlike the native HCBR', activity studies of M234C
indicate that the substrates are not undergoing a re-dox reaction. The fluorimetry data
indicates that the mutant is able to bind anthracyclines although the binding may occur in
a manner that does not facilitate catalysis reactions. These results may indicate that the
catalytic machinery has been interrupted in some way in this enzyme. Further study and
analysis will need to be done to understand what changes have occurred in the substrate
active site of the mutant enzyme.
Comparing between the native and mutant form, the native has slightly more
affinity for both daunorubicin and doxorubicin. The difference is not as great as
compared to the coenzyme data between the two forms of enzyme. Suggesting that the
binding ability of the two forms of enzymes are similar; however, steady state kinetics
indicate that activity varies greatly. Investigation of Met 234’s role in the catalysis
reaction is warranted to understand the difference seen in catalysis but perhaps not in
binding ability of substrates between native and mutant.
The doxorubicin data is very important to this study because our hypothesis was
that we would see a greater ability for the doxorubicin to bind the M234C mutant and
thus see an increased catalytic efficiency. The fluorimetry data does not support this
hypothesis. The native has increased affinity for the doxorubicin molecule compared to
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the M234C mutant. Both the steady state kinetic data and the fluorimetry data disagree
with the stated hypothesis for specific aim 3. These results raise questions as to the role
of Met 234 in the binding of substrates. Perhaps this interaction involves more than just a
steric hindrance in the active site.
Overall, concerning the fluorimetry data the native HCBR' enzyme has more
affinity for all four molecules used compared to the M234C form. All of the results were
surprising and unexpected. The coenzyme data indicate that the histidine tag is
interfering with the binding of substrates and the substrate data indicate that the M234C
is not able to bind doxorubicin with greater affinity.
Circular dichroism studies were done to try and assess the folding ability of both
the NCHBR' and M234C HCBR' enzymes. The folding of the enzyme was also trying to
get at the question as to why the catalysis machinery has been interrupted. If the mutant
enzyme is not folded correctly this could interrupt the catalysis ability of the enzyme.
These experiments suggest that there is no difference in secondary structure between the
native and the M234C HCBR' enzymes. Providing preliminary evidence that M234C
HCBR' may be folded correctly but lacking catalytic activity with the menadione
substrate.
Conclusion
It is difficult to assess the activity of the M234C due to the interruption posed by
the histidine tag. The ideal situation would be to compare the data collected on the
M234C HCBR' mutation to the published literature for the pET5a HCBR enzyme;
however, due to the histidine tag complications it is not possible to do this comparison.
Even though the chosen expression system is not an ideal system it is possible to compare
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the data from the NCHBR' to the M234C HCBR' within reason. It is clear that the
histidine tag is interfering with the binding of the NADPH cofactor; however, it is still
possible to measure activity for the NHCBR'. The M234C mutation can be assumed to
have the similar problems with the histidine tag interfering with NADPH binding. Unlike
the NHCBR' the M234C does not have any measurable activity. This data lends some
support and evidence that the 234 mutations have interrupted the catalysis ability of the
HCBR 1' enzyme. Further study and analysis will need to be done to determine what
roles the 234 position plays in the catalysis reaction.
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CHAPTER 5
FUTURE WORK
IMPROVING THE HIS-TAGGED EXPRESSION SYSTEM FOR HCBR
Reducing the Histidine Tag

Several lines of evidence suggest that the pTrcHis2 TOPO system is not a good
expression system for this protein. The result of this expression vector was a native
protein that did not have the comparable kinetic behavior as that previously published.49
The fact that the histidine tagged protein eluted off in a low imidazole concentration
buffer may also suggest a weak binding of this histidine tag to the nickel resin, perhaps
because of interaction with the remaining protein, thus obscuring the availability of the
histidines to bind to the nickel resin. Overall the character of the protein is compromised
and a new expression system must be explored.
Current research is ongoing to delete the extra DNA bases that code for the extra
23 amino acids that were added with the pTrcHis2 TOPO vector. There are two
techniques that are being used to try and reverse this condition.
One technique utilizes the Phusion site-directed mutagenesis kit. With this kit
primers are designed that flank the region that is to be deleted. One primer starts on the
leading strand at the first histidine and extends the plasmid. The second primer binds the
lagging DNA strand at the end of the HCBR 1 gene and the primer extends the plasmid.
The result is that the region in the middle of the HCBR 1 gene and the His-tag (the
aforementioned 23 added amino acid residues) is removed.
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Another procedure that is being explored is to design a primer with a histidine
overhang that is directly attached to the C-terminus of the HCBR gene. The overhang
will be incorporated into the HCBR 1 gene and the result is that the gene is amplified and
the histidine tag is added to the end of the gene. The amplified gene will then be inserted
back into the pTrcHis2 TOPO expression vector.
If either one of these techniques work the six histidine tag will be added directly
to the end of the gene. Our computer modeling techniques show that the last amino acid
in the protein is on the surface of the HCBR 1 enzyme which is the desired position when
adding a histidine tag. We believe that if the histidine tag can be successfully added to
the last amino acid that the histidine tag will be on the surface of the protein and will be
available to bind to the nickel resin. It seems likely that we will see an increased affinity
for the histidine tagged HCBR 1 to the Ni++ resin and we will observe that an increased
concentration of imidazole will be needed to elute off the protein.
When these experiments are complete we will be looking for several key changes
in the native HCBR 1 protein with histidine tag. First we will be looking to see if the
histidine tag binds to the nickel resin with a higher affinity. We expect the protein to
require higher concentrations of imidazole for elution from the nickel resin because to
date these proteins have been eluting off in a very weak concentration of imidazole. If
the concentration of imidazole needed to elute the protein increases this will indicate a
better binding of the protein to the nickel resin.
Next, kinetic assays will need to be done to fully assess the behavior of the newly
constructed variant of the His-tagged HCBR 1 protein. In order to move forward, the
kinetic behavior of the native must be the same or very similar to the published values for
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HCBR kinetics. If this expression system results in restoring the kinetic behavior than
this expression system will be a better expression system than the current pTrcHis2
TOPO system.
Assess the Activity of Mutated 234 HCBR 1

Once a protocol is established that will remove the extra amino acid residues
added by the initial histidine tag then this procedure will be used to remove the extra
bases from the Cys 234, Ala 234, Ser 234 and Trp 234 genes.
The proteins will be expressed in the established purification protocol. Steady
state kinetics studies will be done to establish if there is or is not activity with these
mutations. If there is observable activity than a kcat, Km and kcat/Km values will be
determined for menadione, daunorubicin, and doxorubicin.
In the event that these mutations continue to lack activity than further experiments
will need to be done to establish the condition of the proteins. One such experiment
could include crystallization of the enzyme with a known substrate. This would give the
researcher an ability to look at a 3-D representation of the enzyme and see if there are
changes in the position of the substrate and the new interaction of the 234 side chain.
Met 141 and Trp 229 Mutated HCBR 1

It is hypothesized that three amino acids work in tandem to guide and dock
substrates in the active site. These three amino acids are Met 234, Met 141 and Trp 229.
Met 234 has been discussed extensively in this paper; however, it is important to mention
the hypothesized role of Met 141 and Trp 229. They are also believed to restrict
substrate binding in the binding pocket via steric hindrance although this mechanism has
not been as clearly defined as the proposed mechanism of Met 234. The Met 141 and Trp
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229 amino acids are observed surrounding the aglycone ring structure of both
daunorubicin and doxorubicin in our computer based models. It is hypothesized that
mutation of these amino acids, individually and in tandem, to amino acids with smaller
side chains such as Cys, Ser or Ala that an effect on the catalytic efficiencies with known
substrates will be observed.
Ongoing research indicates that the Met 141 mutants have activity with the known
substrate menadione, unlike the M234C HCBR' enzyme. The 141 mutant enzymes are
currently in the same histidine tag system as previously mentioned. This limits the ability
to define steady state kinetic values as for 141 mutations as of now. Future experiments
will involve making these mutations in an enzyme construct whereby a histidine tag does
not interfere with enzyme activity. This system may include adding the histidine tag
directly to the end of the enzyme in the same manner as the M234C. Another option is to
remove the histidine tag completely from these specific mutations. Due to the fact that
these mutations currently show activity it may be possible to purify these mutants using
the standard anion exchange purification procedure outlined by Slupe et. al.49 In this
system the data could be directly compared to the published HCBR pET5a steady state
kinetic values leading to the ability to define the changes that have occurred in these
mutations.
Conclusion: Information is the Beginning of Drug Design

The results that are generated from the analyses of 234, 141 and 229 mutations will guide
our understanding of the substrate-enzyme interactions in the active site. This
information is crucial to the rational drug design approach that this laboratory has
undertaken to design a new anthracycline analog. We believe that the information will
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allow a unique design to the anthracycline that will lead to lowered cardiotoxic risk
because the anthracycline analog will resist metabolism by HCBR 1.
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